EUROPEAN HEMATOLOGY ASSOCIATION

23rd Congress of EHA

 

14-17 June 2018 Stockholm
Close
N. Poster
Poster title
Applicant name
Status
  156-PF A NEW HUMANIZED MONOCLONAL ANTIBODY AGAINST A SPECIFIC GLYCOSYLATED EPITOPE OF CD43 ANTIGEN FOR THE THERAPEUTIC TARGETING OF ACUTE LYMPHOBLASTIC LEUKEMIA T (T-ALL) Cirino Botta Received Received
  157-PF CDK8 DEGRADATION - PREPARING THE GROUND FOR MTOR INHIBITION IN BCR/ABL+ ALL Ingeborg Menzl Received Received
  158-PF CD123 X CD3 BISPECIFIC DART® MOLECULE EFFICIENTLY ACTIVATES T CELLS TO KILL PRIMARY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA CELLS Dragana Slavkovic Lukic Received Received
  159-PF POTENT PRECLINICAL ACTIVITIES OF CD9 ANTIBODIES AGAINST HIGH-RISK PEDIATRIC B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA Kam Tong Leung Received Received
  160-PF PRECLINICAL DEMONSTRATION OF INTRACELLULAR ACTIVITY OF ASPARAGINASE ENCAPSULATED IN RED BLOOD CELLS BOTH IN THE ABSENCE AND IN THE PRESENCE OF NEUTRALIZING ANTI-ASPARAGINASE ANTIBODIES Karine Aguera Received Received
  161-PF CIRCULAR RNAOME VARIATION IN NORMAL HEMATOPOIESIS AND MLL REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA Stefania Bortoluzzi Received Received
  163-PF INTEGRATED GENETIC AND EPIGENETIC ANALYSIS ELUCIDATED EXPRESSION AND METHYLATION PROFILES OF ACUTE LYMPHOBLASTIC LEUKEMIA IN DOWN SYNDROME Yasuo Kubota Received Received
  167-PF TARGETING WNT10B*R-MEDIATED AUTOCRINE WNT SIGNALING ACTIVATION IN ACUTE LYMPHOBLASTIC LEUKEMIA Adriana Cassaro Received Received
  168-PF MIR-451 IS A NEW BIOMARKER THAT IDENTIFIES ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WHO MAY BENEFIT FROM TREATMENT WITH NAMPT INHIBITORS Keren Shichrur Received Received
  171-PF S100A16 INHIBITED PROLIFERATION AND PROMOTED APOPTOSIS THROUGH REGULATION OF ERK PATHWAY IN B CELL ALL Jing Zhang Received Received
  172-PF MELATONIN INHIBITS MLL-REARRANGED LEUKEMIA VIA RBFOX3/HTERT AND NF-?B/COX-2 SIGNALING PATHWAYS Yan-Lai Tang Received Received
  173-PF INVESTIGATING THE SYNERGISM BETWEEN CHK1 AND WEE1 PROTEINS INHIBITION IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA Andrea Ghelli Luserna Di Rora Received Received
  185-PF BLINATUMOMAB AND TYROSINE KINASE INHIBITORS COMBINATION IN RELAPSED/REFRACTORY ACUTE LYMPHOBALTIC LEUKEMIA: PRIMARY RESULTS AND LATE EVENTS Andrey Sokolov Received Received
  188-PF LONG TERM OUTCOME OF 138 ALO TRANSPLANTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA ON A SINGLE TRANSPLANT CENTER IN SPAIN Irati Ormazabal Velez Received Received
  189-PF EPIGENOMIC ANALYSIS REVEALS STEM CELL-LIKE RELAPSE SIGNATURE IN PEDIATRIC ACUTE MYELOID LEUKEMIA Caroline Wiggers Received Received
  191-PF NOVEL MUTATIONS AND TRANSLOCATIONS INVOLVING NUCLEOPHOSMIN (NPM1) GENE IN ACUTE MYELOID LEUKEMIA (AML) AND LEADING TO ABERRANT CYTOPLASMIC NPM1 Maria Paola Martelli Received Received
  192-PF THE LSC17 SCORE ALLOWS RISK STRATIFICATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA Nicolas Duployez Received Received
  193-PF MUTATION PROFILE AND BENEFIT OF GEMTUZUMAB OZOGAMICIN IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED IN THE ALFA-0701 TRIAL Elise Fournier Received Received
  194-PF MOLECULAR PATHOGENESIS OF DISEASE PROGRESSION IN MLL-REARRANGED AML Hideki Makishima Received Received
  196-PF THERAPEUTIC TARGETING OF THE LEUKAEMIC FUSION GENE RUNX1/ETO VIA RNAI Hasan Issa Received Received
  198-PF LONGITUDINAL GENOMIC AND TRANSCRIPTOMIC TRACKING OF CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA Taehyung Kim Received Received
  200-PF FUNCTIONAL PROTEOMICS ANALYSIS OF AML-RELATED NUP98-FUSION PROTEIN INTERACTOMES Stefan Terlecki-Zaniewicz Received Received
  201-PF THE PNT DOMAIN OF ERG REGULATES HEMATOPOIETIC STEMNESS, YET IS NOT ESSENTIAL FOR ERG INDUCED ACUTE MYELOID LEUKEMIA Eitan Kugler Received Received
  202-PF FUNCTIONAL ANALYSIS OF EPIGENETIC AND TRANSCRIPTOMIC EFFECTS OF CEBPA MUTATIONS IN ACUTE MYELOID LEUKEMIA Elizabeth Heyes Received Received
  203-PF DETECTION OF MEASURABLE RESIDUAL DISEASE (MRD) BY ULTRADEEP NEXT GENERATION SEQUENCING (NGS) IS HIGHLY PREDICTIVE OF OUTCOME IN NPM1 MUTATED ACUTE MYELOID LEUKEMIA (AML) Nikhil Patkar Received Received
  205-PF NOVEL DEEP TARGETED SEQUENCING METHOD FOR MINIMAL RESIDUAL DISEASE MONITORING IN ACUTE MYELOID? LEUKEMIA Esther Onecha De La Fuente Received Received
  208-PF PROFILING AND FUNCTIONAL ANALYSIS OF CIRCULAR RNAS IN ACUTE PROMYELOCYTIC LEUKEMIA AND THEIR DYNAMIC REGULATION DURING ALL-TRANS RETINOIC ACID TREATMENT Shufen Li Received Received
  210-PF A POSSIBLE FIRST TIER SCREENING TEST TO DETECT TRANSLOCATIONS IN LEUKEMIAS USING TARGETED LOCUS AMPLIFICATION Eva Van Den Berg Received Received
  211-PF FUNCTIONAL EVALUATION AND MECHANISM RESEARCH OF KEL AND CIRC-KEL IN AEL Hui Jin Received Received
  212-PF A NOVEL BET-BROMODOMAIN INHIBITOR, ODM-207, AS A POTENTIAL THERAPY FOR ACUTE MYELOID LEUKEMIA Juho Jalmari Miettinen Received Received
  215-PF SOMATIC MUTATIONS IN RELAPSED ACUTE MYELOID LEUKEMIA Samuli Eldfors Received Received
  216-PF EXPRESSION OF PIWI-INTERACTING RNAS (PIRNAS) AND ITS PROGNOSTIC IMPLICATION IN ACUTE MYELOID LEUKEMIA (AML): A 3-PIRNA SCORING SYSTEM PREDICTS PROGNOSIS IN AML PATIENTS Ta-Chuan Yu Received Received
  217-PF BASOPHIL-LINEAGE COMMITMENT IN ACUTE PROMYELOCYTIC LEUKEMIA PREDICTS FOR SEVERE BLEEDING AFTER STARTING THERAPY Sergio Matarraz Received Received
  220-PF A GROUP OF EMA-APPROVED IMMUNOMODULATORS TARGETS AML STEM CELLS BY SABOTAGING THE CELLULAR RECYCLING MACHINERY Josep Maria Cornet Masana Received Received
  221-PF EXPLORING ALTERNATIVE TREATMENTS TO IMPROVE OUTCOME FOR PEDIATRIC PATIENTS WITH ACUTE MYELOID LEUKEMIA Katrina Lappin Received Received
  222-PF INTEGRATIVE ANALYSIS OF GENOMIC DATA REPOSITIONS THE USE OF 5´-AZACYTIDINE AND DECITABINE IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATMENT maria rosaria sapienza Received Received
  224-PF 5-AZACYTIDINE ENHANCES THE ANTI-LEUKEMIC ACTIVITIY OF IDH1 INHIBITOR BAY 1436032 IN VIVO IN IDH1 MUTANT ACUTE MYELOID LEUKEMIA Anuhar Chaturvedi Received Received
  225-PF COMBINATORIAL CSF3R AND RUNX1 MUTATIONS INVOLVED IN THE LEUKEMIC PROGRESSION OF SEVERE CONGENITAL NEUTROPENIA CONFER A G-CSF-DEPENDENT PREMALIGNANT STATE IN MICE TERMINATING IN G-CSF INDEPENDENT AML Patricia Olofsen Received Received
  226-PF IDENTIFYING NEW DISEASE GENES IN FAMILIAL MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA Ana Rio-Machin Received Received
  227-PF ADDITION OF CRENOLANIB TO STANDARD INDUCTION AND CONSOLIDATION THERAPIES IMPROVED LONG-TERM OUTCOMES IN NEWLY DIAGNOSED FLT3-MUTANT AML PATIENTS = 60 YEARS OLD Roland B. Walter Received Received
  228-PF COMBINATION OF IDARUBICIN, CYTARABINE AND CLADRIBINE AS INDUCTION REGIMEN FOR UNTREATED ADULT AML AGED 60 OR YOUNGER: A PHASE III RANDOMIZED CLINICAL TRIAL Jia Chen Received Received
  229-PF REASSESSING THE PROGNOSTIC SIGNIFICANCE OF RECURRING CHROMOSOMAL ABNORMALITIES AND FLT3-ITD IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: AN ALWP/EBMT ANALYSIS Jonathan Canaani Received Received
  233-PF IMPACT OF CONCOMITANT EXPRESSION OF CD200 AND BCL2 ON OUTCOME OF ACUTE MYELOID LEUKEMIA Mario Tiribelli Received Received
  235-PF CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND T(8;16)(P11;P13): RESULTS FROM AN INTERNATIONAL COLLABORATION Sabine Kayser Received Received
  238-PF SAFETY AND PHARMACOKINETICS OF A NOVEL ORAL CAPSULE FORMULATION OF ARSENIC TRIOXIDE, ORH-2014, IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS Farhad Ravandi-Kashani Received Received
  242-PF RISK FACTORS OF EARLY DEATH FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA UNDER THE TREATMENT OF ATRA, ATO WITH OR WITHOUT CHEMOTHERAPY Li Chen Received Received
  244-PF OUTCOME OF A REAL-LIFE POPULATION OF ACUTE PROMYELOCYTIC LEUKEMIA TREATED ACCORDING TO PETHEMA LPA 2005 PROTOCOL: THE POLISH ADULT LEUKEMIA GROUP (PALG) EXPERIENCE. Marta Sobas Received Received
  247-PF WEEKEND VERSUS WEEKDAY DIAGNOSIS AND EARLY MORTALITY IN ACUTE PROMYELOCYTIC LEUKEMIA: A POPULATION-BASED ANALYSIS IN THE NETHERLANDS Avinash Dinmohamed Received Received
  248-PF DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE REAL LIFE EXPERIENCE FROM THE "ITALIAN TRIVENETO REGISTRY". Carla Fili´ Received Received
  249-PF PROGNOSTIC IMPACT OF SKELETAL MUSCLE ASSESSED BY COMPUTED TOMOGRAPHY SCAN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA Nobuhiko Nakamura Received Received
  250-PF INCIDENCE OF MARROW NEOPLASMS IN BREAST CANCER SURVIVORS: A NATIONAL POPULATION-BASED COHORT STUDY Marie joelle Jabagi Received Received
  251-PF WILMS TUMOR 1 EXPRESSION IN ACUTE MYELOID LEUKEMIA CORRELATES WITH CYTOGENETICS OR COLLABORATIVE MUTATIONS: HOKKAIDO LEUKEMIA NET STUDY Daisuke Hidaka Received Received
  253-PF HYPOMETILATING AGENTS (HMA) AS SALVAGE THERAPY IN RELAPSED OR REFRACTORY AML: AN ITALIAN 9-CENTER RETROSPECTIVE STUDY Marica Laurino Received Received
  255-PF REAL WORLD EVIDENCE ON THE BURDEN OF ILLNESS EXPERIENCED BY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SYSTEMIC MYCOSES Anna Forsythe Received Received
  257-PF AZACITIDINE FRONTLINE AND SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS. CLINICAL EXPERIENCE AND DEVELOPMENT OF RISK SCORE Silvia Imbergamo Received Received
  260-PF IMPACT OF COMORBIDITY ON DISEASE CHARACTERISTICS, TREATMENT INTENT AND OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA – A SWEDISH LYMPHOMA REGISTER STUDY Tove Wästerlid Received Received
  263-PF OVERWEIGHT LYMPHOMA PATIENTS TREATED BY ACTUAL BODY WEIGHT HAD NO EXCESS OF CHEMOTHERAPY TOXICITY: EXPERIENCE FROM TWO LARGE TRIALS Bridgin Merron Received Received
  264-PF QUALITY OF LIFE IN CUTANEOUS T-CELL LYMPHOMA SUBJECTS TREATED WITH THE ANTI-CCR4 MONOCLONAL ANTIBODY MOGAMULIZUMAB VERSUS VORINOSTAT: RESULTS FROM THE PHASE 3 MAVORIC TRIAL Pietro Quaglino Received Received
  266-PF SUBSTITUTION OF CISPLATIN FOR CARBOPLATIN OR OXALIPLATIN IN THE DHAP REGIMEN IS ASSOCIATED WITH IMPROVED SURVIVAL IN RELAPSED/REFRACTORY NON-HODGKIN´S LYMPHOMAS Eloit Martin Received Received
  267-PF VCAP-AMP-VECP VERSUS CHOP AS FIRST-LINE CHEMOTHERAPY FOR AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A PROPENSITY SCORE ANALYSIS Shigeo Fuji Received Received
  269-PF TITLE: LENALIDOMIDE PLUS R-CHOP THERAPY PROVIDES DURABLE LONG-TERM REMISSIONS IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): COMBINED ANALYSIS FROM TWO PHASE 2 TRIALS. Alessia Castellino Received Received
  273-PF MONITORING OF RHOA G17V MUTATION DURING THE COURSE OF THERAPY IN PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA BY QUANTITATIVE ALLELE-SPECIFIC PCR WITH LNA-MODIFIED PRIMERS Yulia Sidorova Received Received
  274-PF CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOME OF ELDERLY SYSTEMIC T/NK CELL LYMPHOMA IN A RESOURCE-LIMITED COUNTRY: THE RESULT OF THAILAND NATIONWIDE LYMPHOMA REGISTRY Kitsada Wudhikarn Received Received
  275-PF RETROSPECTIVE ANALYSIS OF PATIENTS WITH PRIMARY CENTRAL NERVOUS LYMPHOMAS TREATED WITH METHOTREXATE-BASED REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT AND TEMOZOLOMIDE MAINTENANCE Maria Ljungqvist Received Received
  276-PF RITUXIMAB, GEMCITABINE AND OXALIPLATIN (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS NOT CANDIDATES FOR HIGH-DOSE THERAPY WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). A SINGLE CENTER STUDY OF 115 PATIENTS Clarisse Cazelles Received Received
  280-PF SOLUBLE INTERLEUKIN-2 RECEPTOR AS A SURROGATE BIOMARKER OF METABOLIC TUMOR VOLUME MEASURED BY 18F-FDG PET/CT IN DIFFUSE LARGE B-CELL LYMPHOMA Hajime Senjo Received Received
  285-PF CLINICAL RESPONSE AND PHARMACOKINETICS OF BENDAMUSTINE AS A COMPONENT OF SALVAGE R-B(O)AD THERAPY FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) Deok-Hwan Yang Received Received
  286-PF OUTPATIENT SYSTEMIC HIGH-DOSE METHOTREXATE AS CNS PROPHYLAXIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA Rubén Fernández-Alvarez Received Received
  287-PF OUTCOME OF A 10-YEAR POPULATION-BASED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE FIRST-LINE, REFRACTORY AND RELAPSED SETTING: ´REAL-WORLD´ DATA IDENTIFY SUBGROUPS IN NEED OF NEW THERAPIES H.T. van der Galien Received Received
  288-PF LOW SUNLIGHT EXPOSURE AT TIME OF DLBCL DIAGNOSIS MAY BE ASSOCIATED WITH INFERIOR SURVIVAL IN ELDERLY WOMEN Anna Elinder Camburn Received Received
  290-PF CLINICAL CHARACTERISTICS AND OUTCOMES OF BURKITT LYMPHOMA IN A DEVELOPING COUNTRY Wellington Fernandes Da Silva Junior Received Received
  291-PF AN INCREASED RISK OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN CHILDREN AFTER CARDIAC TRANSPLANTATION FOR CONGENITAL HEART DISEASE Ugonna .T. Offor Received Received
  292-PF IDENTIFICATION OF NOVEL MECHANISMS UNDERLYING FUNCTIONAL RESPONSE TO DRUG-INDUCED READTHROUGH OF HAEMOPHILIA B NONSENSE MUTATIONS Mattia Ferrarese Received Received
  293-PF ASSESSMENT OF IMMUNE FUNCTION BEFORE AND AFTER TREATMENT WITH RECOMBINANT FACTOR VIII FUSED WITH FC FRAGMENTS Stephanie P´ng Received Received
  296-PF PREDICTION OF INHIBITORS IN HAEMOPHILIA PATIENTS BY SCORE IN ONE CENTER Oleksandra Stasyshyn Received Received
  298-PF APPLICATION OF THE ISTH BLEEDING SCORE IN HEMOPHILIA Naveena Fatima Received Received
  301-PF PROTEIN EXPLORER IN THE CONTEXT OF OVERLAP OF BONE MARROW FAILURE DISORDERS Ayodele Alaiya Received Received
  303-PF LOW PROPORTION OF MYELOID DERIVED SUPPRESSOR CELL POPULATIONS IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA Nikoleta Bizymi Received Received
  304-PF CLINICAL SIGNIFICANCE OF PNH CLONES IN 3085 PATIENTS WITH CYTOPENIA: A LARGE SINGLE-CENTER EXPERIENCE. Bruno Fattizzo Received Received
  305-PF RA101495, A SUBCUTANEOUSLY-ADMINISTERED PEPTIDE INHIBITOR OF COMPLEMENT COMPONENT C5, FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: PHASE 2 RESULTS Anita Hill Received Received
  307-PF CLINICAL AND MORPHOLOGIC PREDICTORS OF OUTCOME IN APLASTIC ANEMIA PATIENTS TREATED WITH ELTROMBOPAG Bruno Fattizzo Received Received
  308-PF A COMPARATIVE STUDY OF INTENSIVE IMMUNOSUPPRESSIVE THERAPY AND HAPLOIDENTICAL TRANSPLANTATION FOR YOUNG SEVERE APLASTIC ANEMIA miao chen Received Received
  312-PF COMPLEMENT ACTIVATION AND EXACERBATION OF HAEMOLYSIS SECONDARY TO RESPIRATORY VIRAL INFECTIONS IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH) PATIENTS TREATED WITH ECULIZUMAB Ioanna Lazana Received Received
  314-PF THE INCIDENCE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELL CLONES IN THE NORDIC COUNTRIES Christian Kjellander Received Received
  317-PF SMG1 LOSS ENHANCES MTOR SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS Tara Roberts Received Received
  318-PF TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER CHEMOIMMUNOTHERAPY AND IBRUTINIB Luca Vincenzo Cappelli Received Received
  319-PF PAPTP LEADS TO NEOPLASTIC CELL APOPTOSIS IN THE E?-TCL1 CHRONIC LYMPHOCYTIC LEUKEMIA MOUSE MODEL Filippo Severin Received Received
  320-PF OVERTIME ASSESSMENT OF EPIGENETIC PROFILES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY Maria Tsagiopoulou Received Received
  322-PF CLL-DERIVED EXOSOMES REPROGRAM THE PHOSPHOPRTEOMICS LANDSCAPE OF ENDOTHELIAL CELLS. Lian Lipshtein Received Received
  323-PF DYNAMIC REGULATION OF THE HS1/CXCR4 AXIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS Luca Pavesi Received Received
  324-PF CHRONIC LYMPHOCYTE LEUKEMIA CELLS SHARE A UNIQUE CIRCULAR RNA EXPRESSION PATTERN Oshrat Raz Received Received
  325-PF T CELL CLONAL DYNAMICS ARE ASSOCIATED WITH CLINICAL RESPONSE AFTER LENALIDOMIDE CONSOLIDATION TREATMENT IN CLL Anastasia Hadzidimitriou Received Received
  327-PF EVOLUTION OF GENOMIC ABNORMALITIES DURING CLL DISEASE COURSE IS ASSOCIATED WITH TELOMERE LENGTH CHANGES Helena Olbertova Received Received
  328-PF NOTCH1, TP53, SF3B1, ATM AND BIRC3 GENE MUTATIONS ARE ASSOCIATED WITH A WORSE OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13Q LOSSES Ana E Rodríguez-Vicente Received Received
  330-PF GENETIC ABERRATIONS AND PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED CHEMOIMMUNOTHERAPY (FCR/BR): CLINICAL PRACTICE EXPERIENCE Michaela Spunarova Received Received
  331-PF CIRCULATING SEX HORMONES AND NUCLEAR HORMONE RECEPTOR EXPRESSION ARE ASSOCIATED WITH TREATMENT-FREE SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA Katrina Vanura Received Received
  332-PF DESIGN AND MINION TESTING OF A NANOPORE SEQUENCING SPECIFIC GENE PANEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA Francesco Albano Received Received
  333-PF LOW CATALASE EXPRESSION CONFERS REDOX HYPERSENSITIVITY AND IDENTIFIES AN INDOLENT CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA Maria Teresa Scupoli Received Received
  334-PF STAT3 AND STAT5B MUTATIONS IN LARGE GRANULAR LYMPHOCYTES LYMPHOCYTOSIS/LEUKEMIAS: DIAGNOSTIC AND PROGNOSTIC VALUE Noemí Muñoz-García Received Received
  337-PF CG´806, A NON-COVALENT PAN-FLT3/PAN-BTK INHIBITOR, EXHIBITS UNIQUE BINDING TO WILD TYPE AND C481S MUTANT BTK AND GREATER POTENCY THAN IBRUTINIB AGAINST MALIGNANT B CELLS Hongying Zhang Received Received
  341-PF SALVAGE USE OF IBRUTINIB AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA OR MANTLE CELL LYMPHOMA : A STUDY ON BEHALF OF THE SFGM-TC AND THE EBMT Mauricette Michallet Received Received
  343-PF IBRUTINIB FOR FIRST-LINE TREATMENT OF OLDER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL): A 4-YEAR EXPERIENCE FROM THE RESONATE-2 STUDY Jan Burger Received Received
  346-PF SAFETY ANALYSIS OF VENETOCLAX AND IBRUTINIB FOR PREVIOUSLY TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FIRST INTERIM ANALYSIS FROM THE PHASE II VISION HO141 TRIAL Carsten U Niemann Received Received
  347-PF EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: UPDATED RESULTS FROM THE NCRI RIALTO TRIAL. Andrew Pettitt Received Received
  348-PF OBINUTUZUMAB PRE-INDUCTION ABROGATES HIGH TUMOR LYSIS RISK OF VENETOCLAX IN TREATMENT NAÏVE FCR-UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A PLANNED INTERIM ANALYSIS. Mark-David Levin Received Received
  355-PF A PHASE 1 DOSE ESCALATION STUDY OF ARQ 531 IN SELECTED PATIENS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES Jennifer Woyach Received Received
  356-PF EFFECTIVENESS OF IBRUTINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA IN DAILY PRACTICE IN THE NETHERLANDS: A NATIONWIDE POPULATION-BASED COHORT STUDY Lina Van Der Straten Received Received
  357-PF RAPID DOSE ESCALATION OF VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PREVIOUSLY TREATED WITH B-CELL RECEPTOR INHIBITOR THERAPY Kristin Koenig Received Received
  360-PF IMMUNOMODULATORY EFFECTS OF IFN-?LPHA ON T AND NK CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN DEEP MOLECULAR RESPONSE IDENTIFY POTENTIAL CANDIDATES FOR TREATMENT DISCONTINUATION Massimo Breccia Received Received
  361-PF IDENTIFICATION OF GENES DIFFERENTLY EXPRESSED BETWEEN BONE MARROW CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA AT DIAGNOSIS VS. 12 MONTHS OF FIRST-LINE NILOTINIB TREATMENT Alessandra Trojani Received Received
  362-PF NK-CELLS AND LOSS OF MOLECULAR RESPONSE AFTER TKI DISCONTINUATION IN CML PATIENTS Nikolay Kapranov Received Received
  364-PF POLYMORPHISMS IN MULTIDRUG RESISTANCE TRANSPORTER GENES AFFECT THE DURATION OF MOLECULAR RESPONSE TO NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS Federica Loscocco Received Received
  365-PF MYELOID CELL POPULATION DYNAMICS IN TKI-TREATED CML Sieghart Sopper Received Received
  366-PF THE EFFECT OF PREGNANE X RECEPTOR SNP AND TKI TROUGH CONCENTRATION ON CLINIC RESPONSE AND TOXICITY AMONG CHINESE CML PATIENTS. Zhiping Jiang Received Received
  370-PF PREVALENCE AND OUTCOMES OF UNCOMMON BCR-ABL FUSION TRANSCRIPTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DATA FROM A SINGLE CENTER Ya-Zhen Qin Received Received
  372-PF VARIATION IN LIMIT OF BLANK FOR BCR-ABL1 DETECTION BETWEEN LABORATORIES IMPACTS ON SCORING OF DEEP MOLECULAR RESPONSE Helen White Received Received
  373-PF DIGITAL PCR IN PH+ CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION Michele Malagola Received Received
  374-PF FIRST INTERIM ANALYSIS OF THE RUSSIAN MULTICENTER PROSPECTIVE STUDY RU-SKI: DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND DEEP MOLECULAR RESPONSE Ekaterina Chelysheva Received Received
  375-PF RESULTS OF TREATMENT OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PREGNANCY IN ACCORDANCE WITH THE LEUKEMIC BURDEN AND TERM OF PREGNANCY (THE LET SCHEME) Ekaterina Chelysheva Received Received
  376-PF ALLOGENEIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA IN THE TKI ERA: POPULATION BASED DATA FROM THE SWEDISH CML REGISTRY. Anna Lübking Received Received
  378-PF NILOTINIB VERSUS NILOTINIB COMBINED TO PEGYLATED-INTERFERON ALFA 2A IN FIRST-LINE CHRONIC PHASE CML PATIENTS. UPDATED INTERIM ANALYSIS OF A PHASE III TRIAL Franck Nicolini Received Received
  379-PF THE VALUE OF BCR-ABL1 QPCR LEVEL AND DOUBLING TIME (DT) TO PREDICT SUCCESSFUL TREATMENT-FREE REMISSION AFTER IMATINIB DISCONTINUATION: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB (TRAD) TRIAL Dennis Kim Received Received
  380-PF ADDRESSING THE DIAGNOSTIC GAPS IN PYRUVATE KINASE (PK) DEFICIENCY. CONSENSUS RECOMMENDATIONS ON THE DIAGNOSIS OF PK DEFICIENCY Paola Bianchi Received Received
  381-PF IMPLEMENTATION OF THE DIAGNOSTIC WORKFLOW OF HEREDITARY ANEMIAS BY USING TARGETED-NGS PANEL ANALYSIS Roberta Russo Received Received
  382-PF GENETIC MARKERS AND NEW TARGET GENES IN THE DIAGNOSIS OF RARE ANAEMIAS Joan-Lluis Vives-Corrons Received Received
  387-PF HIGH SUCCESS RATE OF TARGETED NEXT GENERATION SEQUENCING FOR THE DIAGNOSIS OF PATIENTS WITH RARE CONGENITAL ANEMIAS Orna Steinberg-Shemer Received Received
  388-PF DIAGNOSIS OF RARE CONGENITAL HEMOLYTIC ANEMIAS ENABLED BY NEXT GENERATION SEQUENCING PANEL Elisa Fermo Received Received
  389-PF NEXT GENERATION SEQUENCING FOR DIAGNOSIS OF INHERITED HEMOLYTIC ANEMIAS Jorge Nieto Received Received
  390-PF REPORT OF THE FIRST CASE OF HEREDITARY SPHEROCYTOSIS DUE TO A LARGE DELETION OF THE SPTA1 GENE Patricia Aguilar-Martinez Received Received
  391-PF CONGENITAL ERYTHROPOIETIC PORPHYRIA AS A MIMICKER OF CHRONIC HEMOLYTIC ANEMIAS IN INFANTS Yasmine El Chazli Received Received
  392-PF CLINICAL CHARACTERISTICS OF PATIENTS WITH RED CELL PYRUVATE KINASE DEFICIENCY IN GERMANY Paraskevi Klothaki Received Received
  393-PF ANTITUMOR ACTIVITY BY TEGS: ALPHA/BETA T CELLS ENGINEERED TO EXPRESS A DEFINED GAMMA/DELTA TCR IN A 3D BONE MARROW NICHE MODEL OF MULTIPLE MYELOMA Jurgen Kuball Received Received
  394-PF DUAL TARGETING STRATEGY OF ACUTE MYELOID LEUKEMIA BY ENGINEERED CYTOKINE-INDUCED KILLER CELLS COEXPRESSING AN INTERLEUKIN 3 CHIMERIC ANTIGEN RECEPTOR (CAR) AND AN ANTI-CD33 COSTIMULATORY RECEPTOR Vincenzo Maria Perriello Received Received
  395-PF SYNERGISTIC T CELL SIGNALING BY CD79A/CD40 COSTIMULATORY ENDODOMAIN ENHANCES CD19 CHIMERIC ANTIGEN RECEPTOR T CELL PROLIFERATION AND SURVIVAL Jakrawadee Julamanee Received Received
  396-PF LENALIDOMIDE AND PROGRAMMED DEATH-1 BLOCKADE SYNERGISTICALLY ENHANCES THE EFFECTS OF DENDRITIC CELL VACCINATION IN A MODEL OF MURINE MYELOMA Je-Jung Lee Received Received
  397-PF RNAI-MEDIATED SILENCING OF ENDOGENOUS TCR ENHANCES TUMOR KILLING ACTIVITY OF TCR-ENGINEERED WT1-SPECIFIC T CELLS Diana Campillo Received Received
  400-PF FIRST-LINE THERAPY WITH DONOR DERIVED HCMV-SPECIFIC T CELLS PROMOTES ANTIVIRAL IMMUNITY BY RESTORING THE QUANTITY AND FUNCTION OF RECIPIENT´S ENDOGENOUS HCMV-SPECIFIC T CELLS AFTER ALLO-HSCT Xiangyu Zhao Received Received
  402-PF THE EFFICACY AND SAFETY OF HUMANIZED CD19 CAR-T CELLS FOR RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (NHL): A PRELIMINARY REPORT Honghui Huang Received Received
  403-PF THE STUDY OF LYMPHOCYTES SUBPOPULATIONS IN PERIPHERAL BLOOD OF PATIENTS WITH AND WITHOUT GVHD PROPHYLAXIS BY MEANS OF MULTIPOTENT MESENCHYMAL STROMAL CELLS AFTER ALLOGENEIC BMT Yulia Davydova Received Received
  404-PF LIVE ATTENUATED VARICELLA ZOSTER VIRUS VACCINATION TO ADULT T-CELL LEUKEMIA/LYMPHOMA PATIENTS CAN INDUCE TUMOR SPECIFIC CELLULAR IMMUNITY. Tatsuro Jo Received Received
  405-PF PRODUCTION OF ARI-0001 CELLS (A3B1:CD8:4-1BB:CD3Z CAR19 CELLS) IN PATIENTS WITH CD19+ RELAPSED/REFRACTORY B-CELL MALIGNANCIES USING THE CLINIMACS PRODIGY SYSTEM Julio Delgado Received Received
  407-PF EARLY GROWTH RESPONSE (EGR)-1 IS A KEY REGULATOR OF HUMAN PRIMARY BONE MARROW STROMA CELLS WITH A DUAL ROLE IN PROLIFERATION AND HEMATOPOIETIC STROMA SUPPORT FUNCTION. Stefan Scheding Received Received
  410-PF HIERARCHICALLY RELATED LINEAGE-RESTRICTED FATES BY MULTIPOTENT HEMATOPOIETIC STEM CELLS Petter Woll Received Received
  414-PF AGE-RELATED CLONAL HEMATOPOIESIS (ARCH) IN CENTENARIANS AND CARDIOVASCULAR DISEASE PATIENTS: A SURVIVAL BIAS HYPOTHESIS Luca Bertamini Received Received
  416-PF ROS-DEPENDENT SELF-RENEWAL DEFECTS OF HUMAN HEMATOPOIETIC STEM CELLS AFTER EXPOSURE TO LOW DOSE OF IONIZING RADIATIONS Marie-Laure Arcangeli Received Received
  417-PF THE HISTONE CHAPERONE NAP1L3 IS REQUIRED FOR HEMATOPOIETIC STEM CELL MAINTENANCE AND DIFFERENTIATION Gözde Turköz Received Received
  418-PF THE IN VIVO EFFECT OF CHEMOTHERAPY AND CXCR4 ANTAGONISM ON AML AND T-ALL CELL MIGRATION IN THE BONE MARROW. Delfim Duarte Received Received
  419-PF PROSPECTIVELY ISOLATED BONE MARROW STROMAL CELLS FROM PATIENTS WITH HEMATOLOGICAL MALIGNANCIES DIFFER PHENOTYPICALLY AND RELATE TO DISEASE STAGE IN MGUS/MYELOMA Stefan Scheding Received Received
  420-PF CD83 IS A NEW POTENTIAL BIOMARKER AND THERAPEUTIC TARGET FOR HODGKIN LYMPHOMA Ziduo Li Received Received
  422-PF TARGETING ROR1 RECEPTOR IN CLASSICAL HODGKIN LYMPHOMA: EFFECTS ON APOPTOSIS AND PROLIFERATION AND ITS EMERGING THERAPEUTIC IMPLICATIONS Louloudenia Velentza Received Received
  423-PF TREATMENT RELATED INCIDENCE OF DISEASES OF THE CIRCULATORY SYSTEM IN PATIENTS DIAGNOSED WITH HODGKIN LYMPHOMA Caroline Weibull Received Received
  425-PF RISK OF SECOND MALIGNANCIES IN HODGKIN LYMPHOMA PATIENTS IN THE NEW MILLENNIUM: REAL WORLD EVIDENCE FROM THE SEER DATABASE Velizar Shivarov Received Received
  427-PF INTERIM- PET RESULTS FOR PROGNOSIS IN ADULTS WITH HODGKIN LYMPHOMA: A PROGNOSTIC FACTOR EXEMPLAR REVIEW (PRELIMINARY RESULTS) Angela Aldin Received Received
  428-PF DOWNREGULATION OF STATS DETERMINE POOR PROGNOSIS IN HODGKIN´S LYMPHOMA. Stephen Ting Received Received
  430-PF PAEDIATRIC HODGKIN LYMPHOMA IN VERY YOUNG PATIENTS: THE ITALIAN EXPERIENCE Piero Farruggia Received Received
  432-PF THE COMBINATION OF ALISERTIB AND ROMIDEPSIN IS A SAFE AND EFFECTIVE REGIMEN FOR RELAPSED/REFRACTORY AGGRESSIVE HODGKIN AND T-CELL LYMPHOMAS: A PHASE 1 STUDY Paolo Strati Received Received
  433-PF ?SUVMAX AND ?SUVPEAK IMPROVE THE NEGATIVE PREDICTIVE VALUE OF INTERIM PET SCAN IN HODGKIN LYMPHOMA Teresa Ribeiro Received Received
  434-PF OUTCOME OF ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA IN CENTRAL SCOTLAND, UK Mark Rafferty Received Received
  440-PF AUTOLOGOUS STEM CELL TRANSPLANTATION MAY CURE FOLLICULAR LYMPHOMA PATIENTS WITH EARLY THERAPY FAILURE WHO REACH COMPLETE RESPONSE AFTER RESCUE TREATMENT IRRESPECTIVE OF PREVIOUS RITUXIAMB EXPOSURE. Ana Jiménez Ubieto Received Received
  441-PF RESULTS OF A DOSE ESCALATION STUDY OF ME-401, A SELECTIVE PI3K? INHIBITOR, IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) John M Pagel Received Received
  442-PF SHORT DIAGNOSIS TO TREATMENT INTERVAL IS ASSOCIATED WITH POOR OUTCOMES IN PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH IMMUNOCHEMOTHERAPY Michael R Clausen Received Received
  443-PF NEW ASSESSMENT INDEX OF CLINICAL TRANSFORMATION FROM FOLLICULAR LYMPHOMA (FL) TO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA Takafumi Shichijo Received Received
  446-PF R-ESHAP IS NOT EFFECTIVE AS SALVAGE THERAPY IN REFRACTORY FOLLICULAR LYMPHOMA: RESULTS OF A RETROSPECTIVE MULTICENTRE STUDY ON BEHALF OF GELCAB GROUP Ana Muntañola Received Received
  449-PF COMPARATIVE EFFICACY AND SAFETY OF DIFFERENT ANTIVIRAL AGENTS FOR CYTOMEGALOVIRUS PROPHYLAXIS AFTER HEMATOPOIETIC-CELL TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSES Nico Gagelmann Received Received
  450-PF CANDIDA-REACTIVE T CELLS FOR THE DIAGNOSIS OF INVASIVE CANDIDA INFECTION Felix Koehler Received Received
  451-PF TENOFOVIR VERSUS LAMIVUDINE FOR PREVENTION OF HEPATITIS B VIRUS REACTIVATION AMONG PATIENTS WITH AGGRESSIVE LYMPHOMAS UNDERGOING FRONT-LINE ANTHRACYCLINE-CONTAINING CHEMOTHERAPY Irene Zacheo Received Received
  453-PF MURCORMYCOSIS AND ASPERGILLOSIS IN ONCOHEMATOLOGICAL PATIENTS: WHAT´S THE DIFFERENCE? Nikolay Klimko Received Received
  454-PF INVASIVE FUNGAL DISEASES CAUSED BY RARE PATHOGENS IN CHILDREN WITH HEMATOLOGICAL DISEASES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CHEMOTHERAPY Marina Olegovna Popova Received Received
  455-PF INVASIVE ASPERGILLOSIS IN HAEMATOLOGICAL PATIENTS: A REVIEW OF 625 CASES Raoul Herbrecht Received Received
  456-PF DIAGNOSIS OF INVASIVE ASPERGILLOSIS IN HIGH RISK HEMATOLOGICAL MALIGNANCY PATIENTS: PERFORMANCE OF BIOMARKERS AND CYTOKINES IN SAME DAY BLOOD AND BRONCHOALVEOLAR LAVAGE FLUID SAMPLES. Hoenigl Martin Received Received
  457-PF NEUTROPHIL EXTRACELLULAR TRAPS IMPAIR FUNGAL CLEARANCE IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS Astrid Alflen Received Received
  458-PF HEMOPHAGOCYTIC LIMPHOHISTIOCYTOSIS ASSOCIATED WITH LEISHMANIASIS: A HIDDEN PASSENGER IN ENDEMIC AREAS? Jon Badiola Received Received
  460-PF ANTIGFUNGAL DRUGS MODULATE HUMAN NEUTROPHIL ACTIVITIES IN VITRO AND IN VIVO IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Daniel Teschner Received Received
  461-PF (1-3)-?-D-GLUCAN ASSAY AND AIRWAY-INVASIVE RADIOLOGICAL FINDINGS AS EARLY SIGNS OF PULMONARY ASPERGILLOSIS IN HIGH-RISK HEMATOLOGIC PATIENTS IN THE POSACONAZOLE ERA: PRELIMINARY OBSERVATIONS Claudia Giordano Received Received
  462-PF COMPARATIVE ANALYSIS OF DETECTION OF EBV SMALL NON-CODING RNA (EBER) AND MARKERS OF ACUTE EBV INFECTION AT THE ONSET OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA Natalia Chernova Received Received
  463-PF THE ROLE OF SERUM GALACTOMANNAN ASSAY IN THE MANAGEMENT OF INVASIVE MOLD INFECTIONS IN AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. Maria Esther Martinez-Muñoz Received Received
  464-PF CYTOMEGALOVIRUS (CMV) IMPACT ON CLINICAL OUTCOMES AND RESOURCE USE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: THE INFLUENCE OF RECURRENT EPISODES OF CMV INFECTION Carlos de Miguel Received Received
  465-PF EPIDEMIOLOGY AND TREATMENT APPROACHES OF INVASIVE FUNGAL INFECTIONS MANAGEMENT IN HEMATOLOGICAL MALIGNANCIES: RESULTS FROM A SINGLE-CENTRE STUDY Katarina Gluic Received Received
  466-PF HERPES VIRUSES AT THE ONSET OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA. IS THERE AN ASSOCIATION? Dmitry Tikhomirov Received Received
  467-PF POST-TRANSPLANT EBSTEIN-BARR VIRAL LOAD MONITORING EXPERIENCE IN A HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTER Mürüvvet Seda Aydin Received Received
  468-PF ISAVUCONAZOLE SHORTENS THE QTC INTERVAL Sibylle Mellinghoff Received Received
  469-PF ALPHA LIPOIC ACID REDUCES THE TOXIC EFFECTS INDUCED BY IRON OVERLOAD TREATMENT: IN VITRO AND IN VIVO MODELS Giuseppina Camiolo Received Received
  470-PF A PHASE 1, PLACEBO-CONTROLLED STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ESCALATING SUBCUTANEOUS DOSES OF LJPC-401 (SYNTHETIC HUMAN HEPCIDIN) IN HEALTHY ADULTS Eva Hortas Received Received
  471-PF REPEATABILITY OF LIVER IRON CONCENTRATION MEASUREMENTS WITH MRI AND AN ARTIFICIAL NEURAL NETWORK DATA ANALYSIS SYSTEM Tim St Pierre Received Received
  473-PF IRON OVERLOAD IN RARE HEREDITARY HEMOLYTIC ANEMIA Stephanie van Straaten Received Received
  474-PF IRON OVERLOAD INCREASES OXIDATIVE STRESS AND DECREASES CLONOGENIC CAPACITY OF CELLS IN MDS PATIENTS: CAN BE RESTORED AFTER DEFERASIROX TREATMENT? Tamara Jiménez Solas Received Received
  476-PF TISSUE IRON OVERLOAD ASSESSMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA Kira Lukina Received Received
  478-PF A RARE CAUSE OF HEREDITARY HEMOCHROMATOSIS : COMPOUND HETEROZYGOSITY ASSOCIATING THE C282Y VARIATION WITH A PRIVATE HFE MUTATION - TWO CASES COMBINING NEW NONSENSE MUTATIONS. Severine Cunat Received Received
  480-PF SOMATIC MUTATIONS AS MARKERS OF OUTCOME AFTER AZACITIDINE TREATMENT FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTION (HSCT) IN HIGHER-RISK (HR) MDS AND LOW-BLAST COUNT ACUTE MYELOID LEUKEMIA (LBC-AML) Giulia Falconi Received Received
  481-PF SYNERGISTIC EFFECTS OF PRIMA-1MET (APR-246) AND AZACITIDINE (AZA) IN TP53-MUTATED MYELODYSPLASTIC SYNDROMES Nabih Maslah Received Received
  482-PF GENE PANEL ANALYSIS BY NEXT GENERATION SEQUENCING FOR THE DETECTION OF CLONAL HAEMATOPOIESIS IN IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) AND MYELODYSPLASTIC SYNDROME (MDS) Yannick Wouters Received Received
  485-PF ASXL1 IS A MOLECULAR PREDICTOR IN IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE Dong-Yeop Shin Received Received
  488-PF USING PU.1 AND JUN DIMERIZATION PROTEIN 2 TRANSCRIPTION FACTOR EXPRESSION IN MYELODYSPLASTIC SYNDROMES TO PREDICT TREATMENT RESPONSE AND LEUKEMIA TRANSFORMATION Ciro Rinaldi Received Received
  490-PF A NOVEL CULTURE MODEL FOR STUDYING TERMINAL ERYTHROID DIFFERENTIATION IN PATIENTS WITH SF3B1 MUTATED MYELODYSPLASTIC SYNDROMES Edda María Elvarsdóttir Received Received
  491-PF PROGNOSTIC SIGNIFICANCE OF THE ASXL1 GENE ALTERATION IN PATIENTS WITH ISOLATED 20Q DELETION Jana Brezinova Received Received
  492-PF PARP1 EXPRESSION PROFILE AND DIVERGENT CLINICAL IMPACT IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA. Ana María Hurtado López Received Received
  494-PF MECHANISTIC CHARACTERIZATION OF HDACI MEDIATED KIT DOWNREGULATION IN SYSTEMIC MASTOCYTOSIS Katarina Lyberg Received Received
  496-PF DESCRIPTION OF MUTATIONAL PROFILE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES AT THE TIME OF LEUKEMIC PROGRESSION Begoña Pedrote Received Received
  497-PF CLONAL EVOLUTION IS MUCH MORE FREQUENT IN MDS AS KNOWN AS YET Christina Ganster Received Received
  499-PF ROLE OF SOMATIC MUTATIONS IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH ERYTHROPOIESIS STIMULATING AGENTS Juan Carlos Caballero Received Received
  500-PF MOLECULAR SCORING SYSTEM INTEGRATED WITH IPSS-R IN KOREAN MYELODYSPLASTIC SYNDROME Hee Sue Park Received Received
  501-PF PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND MULTILINEAGE DYSPLASIA WITH OR WITHOUT RING SIDEROBLASTS. Abhishek Mangaonkar Received Received
  502-PF CLINICAL OUTCOMES OF PATIENTS WITH MDS/MPN OVERLAP SYNDROMES Simon Kavanagh Received Received
  503-PF FLOW CYTOMETRY ANALYSIS OF ERYTHROPOIETIC MATURATION PATTERNS HELP TO DIAGNOSE AND FOLLOW-UP ERYTHROPOIETIC DYSPLASIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES Despoina Violidaki Received Received
  506-PF DIFFERENCES IN MUTATIONAL PROFILE AND CLONAL ARCHITECTURE OF MYELODYSPLASTIC SYNDROMES WITH ISOLATED DELETION OF 5Q, HYPERPLASTIC AND HYPOPLASTIC MYELODYSPLASTIC SYNDROMES Francisca Hernández Mohedo Received Received
  507-PF CLINICAL SIGNIFICANCE OF REDUCED EXPRESSION OF THE GENES LOCATED WITHIN COMMON DELETED REGION OF DEL(20Q) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES Masayuki Shiseki Received Received
  508-PF HIGH WT1 EXPRESSION LEVELS AT DIAGNOSIS PREDICTED POOR OUTCOMES OF PATIENTS PRESENTING ISOLATED THROMBOCYTOPENIA AT ONSET OF MYELODYSPLASTIC SYNDROME Qiu-Sha Huang Received Received
  509-PF ROLE OF DNA METHYLATION GENE AND TP53 MUTATIONS IN PREDICTING THE CLINICAL EFFICACY OF EPIGENETIC THERAPY IN MYELOID NEOPLASM PATIENTS - META ANALYSIS Li Cai Received Received
  510-PF THE EVALUATION OF OXIDATIVE STRESS AND IRON METABOLISM MARKERS IN MYELODYSPLASTIC SYNDROMES Mihnea-Alexandru Gaman Received Received
  511-PF MUTATIONS IN 19S PROTEASOME SUBUNITS REPRESENT A NOVEL MECHANISM OF ACQUIRED RESISTANCE TO PROTEASOME INHIBITORS IN MULTIPLE MYELOMA PATIENTS Santiago Barrio Received Received
  512-PF EXPRESSION OF P53 ISOFORMS AT MRNA LEVEL IN MULTIPLE MYELOMA: IMPLICATIONS FOR CLINICAL OUTCOME Elizabeta De Los Angeles Rojas Received Received
  514-PF ADAR1-MEDIATED-A-TO-I-EDITING IS BIOLOGICALLY AND CLINICALLY RELEVANT IN MULTIPLE MYELOMA Phaik Ju Teoh Received Received
  515-PF MOLECULAR MECHANISMS OF THE ACTIVITY OF THE NOVEL C-MYC TARGETED-COMPOUND IDP-501 IN MM Patryk Krzeminski Received Received
  516-PF SNPS ARRAY ANALYSIS OF COPY NUMBER ALTERATIONS (CNAS) IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS: DEFINITION OF A PROGNOSTIC RISK-CLASSIFIER. Carolina Terragna Received Received
  517-PF PEPTIDE STIMULATION OF PD-L1 SPECIFIC T CELLS NATURALLY OCCURING IN MYELOMA PATIENTS AUGMENT THE ADCC ACTIVITY OF DARATUMUMAB Nicolai Grønne Jørgensen Received Received
  518-PF NOVEL KINASE INHIBITORS AFURESERTIB AND PIM447 ARE ACTIVE IN A PREDICTIVE MYELOMA IN VIVO MODEL, AND A CRISPR GENOME-WIDE SCREENING APPROACH IDENTIFIES BIOMARKERS DETERMINING SUSCEPTIBILITY Niamh Keane Received Received
  519-PF CD26 IS A POTENTIAL THERAPEUTIC TARGET BY HUMANIZED MONOCLONAL ANTIBODY IN MULTIPLE MYELOMA Hiroko Nishida Received Received
  520-PF DNA REPAIR PROCESSES TARGET TRANSCRIBED REGION IN MULTIPLE MYELOMA eva hortas Received Received
  522-PF STUDY OF PLASMA CELL TRASCRIPTOME IN SMOLDERING MYELOMA PATIENTS IN RELATIONSHIP TO PROGRESSION TO ACTIVE MULTIPLE MYELOMA. Paola Storti Received Received
  523-PF GENOMIC CHARACTERIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MULTIPLE MYELOMA REVEALS DISTINCT PATTERNS OF DISEASE EVOLUTION Aino-Maija Leppä Received Received
  524-PF LONGITUDINAL CHROMOSOMAL ABNORMALITIES ANALYSIS IN MULTIPLE MYELOMA DISEASE PROGRESSION REVEALS CLONAL EVOLUTION AFTER THERAPY. Stefania Oliva Received Received
  526-PF RAPID AND SCALABLE GENOME-WIDE PROFILING OF CLINICALLY RELEVANT GENETIC ABERRATIONS IN MULTIPLE MYELOMA Donat Alpar Received Received
  528-PF RNA-SEQ BASED RISK STRATIFICATION IN MULTIPLE MYELOMA PATIENTS VALIDATES SKY92 AS A HIGH RISK MARKER IN THE COMMPASS TRIAL Rowan Kuiper Received Received
  529-PF MDSCS CONTRIBUTE TO CANCER STEM CELLS ACCUMULATION VIA PIRNA 823 UPREGULATION AND DE NOVO DNA METHYLATION IN MULTIPLE MYELOMA Lisha Ai Received Received
  531-PF LOW-PASS SEQUENCING OF PLASMA CELL DNA AND OF CIRCULATING CELL-FREE DNA FOR THE DETECTION OF COPY NUMBER ABERRATIONS AND EARLY RESPONSE MONITORING IN MULTIPLE MYELOMA Barbara Dewaele Received Received
  532-PF RNA-SEQ ANALYSIS UNRAVELS SPECIFIC LONG NON-CODING RNA TRANSCRIPTIONAL FINGERPRINTS IN MULTIPLE MYELOMA SUBTYPES Elisa Taina Received Received
  533-PF COMBINATION TARGETING OF SIALYLATION AND THE PROTEASOME INHIBITS TUMOR GROWTH AND INCREASES SURVIVAL IN A HUMANIZED MOUSE MULTIPLE MYELOMA MODEL Michaela Reagan Received Received
  534-PF ACTIVATION OF NFAT (NUCLEAR FACTOR OF ACTIVATED T CELLS) SIGNALING AND INDUCTION OF AUTOPHAGY CONFER BORTEZOMIB RESITSTANCE IN MULTIPLE MYELOMA Margaret Ng Received Received
  535-PF THE CONICAL AGAROSE MICROWELL ARRAY (CAMA) ENABLES 3D LONG-TERM CULTIVATION OF PRIMARY SAMPLES AND ENHANCED HIGH THROUGHPUT SCREENING FOR RATIONAL EPIGENTIC/ANTIBODY COMBINATION IN MULTIPLE MYELOMA Stefan J. Mueller Received Received
  536-PF ENHANCED CYTOTOXICITY OF MULTIPLE MYELOMA CELLS USING DARATUMUMAB IN COMBINATION WITH NK CELLS ENGINEERED TO EXPRESS HIGH-AFFINITY CD16 (F158V) Michael O´Dwyer Received Received
  537-PF IMMUNOLOGICAL PROFILING BY MASS CYTOMETRY REVEALS THAT TIM3 EXPRESSION IS REDUCED ON NK CELL SUBSETS IN NEWLY DIAGNOSED MYELOMA AND IS ASSOCIATED WITH LOSS OF NK FUNCTION AND DECREASED SURVIVAL Frances Seymour Received Received
  540-PF MDSCS PROMOTED TUMORIGENESIS OF MULTIPLE MYELOMA BOTH IN VITRO AND IN VIVO. Lisha Ai Received Received
  541-PF TARGETING THE INTERACTION OF MULTIPLE MYELOMA AND THE BONE MARROW MICROENVIRONMENT THROUGH NOVEL SMALL MOLECULES DIRECTED TO NOTCH PATHWAY Natalia Platonova Received Received
  542-PF EXPRESSION LEVELS OF THE THREE GENES CRBN, IKZF1, AND IKZF3 IN PRIMARY MULTIPLE MYELOMA CELLS AT PRE- AND POST- LENALIDOMIDE TREATMENT Shiori Kinoshita Received Received
  543-PF MYC INVOLVES MULTIPLE MYELOMA PROGRESSION BY ATTENUATING TUMOR SUPPRESSIVE FUNCTION OF TP53-MICRO RNA 34 AXIS Yuki Murakami Received Received
  545-PF TRYPTOPHAN SHORTAGE DUE TO IDO-1 EXPRESSED BY HIGH-DENSITY NEUTROPHILS INDUCE IMMUNE-SUPPRESSION AND PLASMA CELL FITNESS IN MULTIPLE MYELOMA Alessandra Romano Received Received
  546-PF CHARACTERIZATION OF ST3GAL6-AS1, A NOVEL LNCRNA DEREGULATED IN MULTIPLE MYELOMA Cristina Vinci Received Received
  547-PF MULTIPLE MYELOMA RELATED ANGIOGENESIS: ROLE OF NOTCH-JAG AXIS IN MODULATING ENDOTHELIAL CELLS BEHAVIOR Maria Teresa Palano Received Received
  548-PF ADIPORON, THE FIRST ORAL ADIPONECTIN RECEPTOR AGONIST, INHIBITS THE PROLIFERATION OF MYELOMA CELLS VIA THE AMPK / MTOR /AUTOPHAGY SIGNALING PATHWAY Shujuan Wang Received Received
  549-PF CLINICAL RELEVANCE OF LONG NON CODING RNA IN MULTIPLE MYELOMA: RETROSPECTIVE MONOCENTRIC STUDY Valeria Ferla Received Received
  550-PF DRUG SENSITIVITY SCREENING IN MULTIPLE MYELOMA (MM) FOR PRECISION CANCER THERAPY Deepak Balaji Thimiri Govinda Raj Received Received
  552-PF DISCOVERY BLOOD PLASMA PROTEOMICS IN ELUCIDATING BIOMARKERS TO DISTINGUISH ONSET OF LETHAL MULTIPLE MYELOMA IN PREMALIGNANT MGUS Luz Yurany Moreno Received Received
  553-PF VARIABLES PREDCITVE OF POOR PROGNOSIS IN PATIENTS WITH MAYO STAGE 1 SYSTEMIC LIGHT CHAIN AMYLOIDOSIS Faye Sharpley Received Received
  554-PF SINGLE AGENT CARFILZOMIB PROLONGS PFS FOLLOWING TRIPLET THERAPY WITH CYCLOPHOSPHAMIDE & DEXAMETHASONE FOR FIRST RELAPSE/PRIMARY REFRACTORY MULTIPLE MYELOMA: PHASE 2 MUKFIVE STUDY, SECOND ANALYSIS Kwee Yong Received Received
  556-PF LEVOFLOXACIN PROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA REDUCES FEBRILE EPISODES AND DEATH WITHOUT INCREASING HEALTHCARE ASSOCIATED INFECTIONS: RESULTS FROM THE TEAMM TRIAL Stella Bowcock Received Received
  557-PF PROGNOSTIC SIGNIFICANCE OF MAGNETIC RESONANCE IMAGING BEFORE AND AFTER UPFRONT AUTOLOGOUS TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA – A SUBGROUP ANALYSIS FROM THE GMMG MM5 PHASE III TRIAL Maximilian Merz Received Received
  560-PF CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG) Francesca Gay Received Received
  566-PF TIME TO PLATEAU AS A PREDICTOR OF SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA Patrick Mellors Received Received
  568-PF PRE-TREATMENT CD38 EXPRESSION LEVELS IN MYELOMA CELLS AND CD38-POSITIVE REGULATORY T CELLS AFFECT THE RESPONSE OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TO TREATMENT WITH DARATUMUMAB Akihiro Kitadate Received Received
  569-PF UPDATED RESULTS OF A PHASE II STUDY WITH CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCD) FOR NEWLY DIAGNOSED TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS. Alessandra Larocca Received Received
  570-PF DEVELOPMENT OF A PREDICTIVE MODEL OF MULTIPLE MYELOMA (MM) PATIENT OUTCOMES BASED ON TREATMENT (TX) SEQUENCING USING DATA FROM THE CONNECT® MM PATIENT REGISTRY Sundar Jagannath Received Received
  575-PF SMOLDERING MYELOMA AFTER IMWG UPDATE: FACTORS PREDICTIVE OF EVOLUTION, ROLE OF ADVANCED IMAGING AND OF CLINICAL JUDGEMENT. A REAL-LIFE RETROSPECTIVE EXPERIENCE Lorenza Torti Received Received
  577-PF CLINICAL CHARACTERISTICS AND OUTCOMES OF OLIGOSECRETORY AND NON-SECRETORY MULTIPLE MYELOMA Efstathios Kastritis Received Received
  578-PF SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN INDEPENDENTLY PREDICTS FOR RENAL RESPONSE IN MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT Efstathios Kastritis Received Received
  580-PF LONG-TERM RESULTS FROM THE HOVON-50 STUDY: IMPROVED SURVIVAL WITH THALIDOMIDE BEFORE AND AFTER TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA Niels Van De Donk Received Received
  584-PF UPDATE OF THE PHASE 2 STUDY OF CARFILZOMIB, THALIDOMIDE, AND LOW-DOSE DEXAMETHASONE AS INDUCTION/CONSOLIDATION IN NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA, CARTHADEX TRIAL Ruth Wester Received Received
  585-PF CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED PATIENTS WITH AL AMYLOIDOSIS WITH "NON-MEASURABLE" FREE LIGHT CHAINS: PROGNOSTIC IMPLICATIONS AND RESPONSE EVALUATION Efstathios Kastritis Received Received
  587-PF ABSENCE OF BONE DISEASE IS AN INDEPENDENT FAVORABLE PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN SYMPTOMATIC MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS Eirini Katodritou Received Received
  588-PF CORRELATION OF 11C-METHIONINE-PET AND FDG-PET IN MULTIPLE MYELOMA WITH MRD ASSESSMENT BY FLOWCYTOMETRY. María Marcos Received Received
  589-PF TRANSLOCATION (14;16) POSITIVE MULTIPLE MYELOMA PATIENTS: CLINICAL FEATURES AND SURVIVAL OUTCOMES OF A HIGH-RISK POPULATION. Roberto Mina Received Received
  590-PF THE SWEDISH MYELOMA REGISTRY: INCREASED SURVIVAL OVER TIME IN PATIENTS 66-80 YEARS OLD, DIAGNOSED 2008-2016 Cecilie Hveding Blimark Received Received
  591-PF 18F-FDG PET/CT AT DIAGNOSIS IS USEFUL FOR DETERMINING THE SURVIVAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA CLASSIFIED AS STAGE II WITH THE REVISED INTERNATIONAL STAGING SYSTEM Sung-Hoon Jung Received Received
  593-PF IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA – DATA FROM THE CZECH REGISTRY OF MONOCLONAL GAMMOPATHIES Jiri Minarik Received Received
  594-PF ALLOGRAFT IN MULTIPLE MYELOMA: EXPERIENCE OF MULTIPLE MYELOMA GIMEMA LAZIO GROUP Federico Vozella Received Received
  596-PF MP0250 IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA: FIRST SAFETY AND EARLY EFFICACY ANALYSIS OF MP0250-CP201 Eva Hortas Received Received
  597-PF STATIN USE IMPROVES MYELOMA-SPECIFIC SURVIVAL AND IS SAFE TO USE IN LYMPHOMA: A POPULATION-BASED STUDY OF 20,464 PATIENTS WITH LYMPHOID MALIGNANCIES DIAGNOSED IN SWEDEN 2007-2013 Elsa Brånvall Received Received
  598-PF A PROSPECTIVE ANALYSIS ON THE FREQUENCY AND PREDICTIVE VALUE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY FLOW CYTOMETRY AND PET-CT IMAGING AMONG MYELOMA PATIENTS ON/OFF MAINTENANCE Meral Beksac Received Received
  599-PF EARLY RELAPSE IS A POWERFUL INDEPENDENT NEGATIVE PREDICTOR FOR OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS Eirini Katodritou Received Received
  600-PF SENSIVITY AND CLINICAL VALUE OF POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY AND WHOLE BODY MAGNETIC RESONANCE IMAGING TO ASSESS BONE DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA. Elena Fernandez-Poveda Received Received
  601-PF ANTI-SLAMF7 ANTIBODY SUPPRESSES FIBROCYTE DIFFERENTIATION AS A POTENT THERAPEUTIC AGENT FOR MYELOFIBROSIS Takaaki Maekawa Received Received
  603-PF PHARMACOLOGIC TARGETING OF NEOPLASTIC STEM CELLS IN HUMAN MAST CELL LEUKEMIA Gregor Eisenwort Received Received
  604-PF THE PHENOTYPIC PROFILE OF ACUTE MYELOID LEUKEMIA SECONDARY TO CHRONIC MYELOPROLIFERATIVE NEOPLASMS: RESULTS OF A MULTI-CENTER STUDY Francesco Mannelli Received Received
  606-PF PATIENT-DERIVED INDUCED PLURIPOTENT STEM CELLS REVEALED CALCIUM/CALMODULIN DEPENDENT PROTEIN KINASE 2 AS A POTENTIAL THERAPEUTIC TARGET OF MYELOFIBROSIS Masashi Miyauchi Received Received
  607-PF MUTATIONAL MECHANISMS OF EZH2 INACTIVATION IN MYELOID NEOPLASMS Andrew Chase Received Received
  609-PF SDF1 ?LPHA-INDUCED CHEMOTAXIS OF JAK2-V617F POSITIVE CELLS IS DEPENDENT ON BRUTON´S TYROSINE KINASE AND PHOSPHOLIPASE C GAMMA 1 Subbaiah Chary Nimmagadda Received Received
  613-PF DURABILITY OF SPLEEN RESPONSE MAY AFFECT OUTCOME OF RUXOLITINIB-TREATED PATIENTS WITH MYELOFIBROSIS: RESULTS FROM A MULTICENTRE STUDY ON 284 PATIENTS Francesca Palandri Received Received
  614-PF DEVELOPMENT OF A PROGNOSTICALLY RELEVANT ´CACHEXIA INDEX´ IN PRIMARY MYELOFIBROSIS USING SERUM ALBUMIN AND CHOLESTEROL LEVELS Maura Nicolosi Received Received
  615-PF PATIENTS WITH LOW JAK2 ALLELE BURDEN HAVE A HIGH RATE OF CO-OCCURRENT CALR MUTATIONS BEARING AN EFFECT ON DISEASE PHENOTYPE IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS. Barbara Mora Received Received
  617-PF HIGH RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN BCR-ABL-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS AFTER TERMINATION OF ANTICOAGULATION Kai Wille Received Received
  619-PF MUTATIONAL LANDSCAPE AND ITS IMPACT ON OUTCOMES IN ACCELERATED AND BLAST PHASE OF MYELOPROLIFERATIVE NEOPLASMS Caroline Mcnamara Received Received
  620-PF SAFETY AND EFFICACY OF COMBINATION THERAPY OF INTERFERON ?LPHA-2 AND RUXOLITINIB IN POLYCYTHEMIA VERA AND LOW-/INTERMEDIATE-1-RISK MYELOFIBROSIS – A ONE YEAR FOLLOW-UP UPDATE OF A PHASE II STUDY Stine Ulrik Mikkelsen Received Received
  624-PF PRIMARY THERAPY AND SURVIVAL IN PRIMARY MYELOFIBROSIS: A NATIONWIDE POPULATION-BASED ANALYSIS AMONG 1,445 PATIENTS DIAGNOSED IN THE NETHERLANDS BETWEEN 2001 AND 2015 Avinash Dinmohamed Received Received
  629-PF RELATIONSHIP BETWEEN MPN PAIN AND EMOTIONAL HEALTH: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP Robyn Scherber Received Received
  630-PF ANALYSIS OF IPSET-THROMBOSIS VS R-IPSET-THROMBOSIS IN A POPULATION OF 776 ESSENTIAL THROMBOCYTHEMIA PATIENTS - A MULTICENTER RETROSPECTIVE STUDY. Marta Sobas Received Received
  631-PF SKEWED RATIO BETWEEN TYPE 1 AND TYPE 2 CALR MUTATIONS IN ESSENTIAL THROMBOCYTOSIS PATIENTS WITH CONCOMITANT JAK2 V617F MUTATION Anni Aggerholm Received Received
  632-PF CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN: NEW INSIGHTS INTO A NOVEL AND STILL ENIGMATIC ENTITY Aliki Xochelli Received Received
  634-PF MYC-MEDIATED DOWNREGULATION OF MIR-150 CONTRIBUTES TO THE TRANSFORMATION OF FOLLICULAR LYMPHOMA BY UPREGULATING FOXP1 LEVELS Katerina Musilova Received Received
  635-PF THE AXL TYROSINE KINASE INHIBITOR, BGB324, INDUCES CELL DEATH IN MANTLE CELL LYMPHOMA Pascal Gelebart Received Received
  640-PF ELEVATED SERUM IL-8, IL-10, IL-22, AND MCP-1 ARE ASSOCIATED WITH INFERIOR CLINICAL OUTCOMES IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA Jun Ho Yi Received Received
  641-PF BIOMARKER ANALYSES OF PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, OR RICHTER´S TRANSFORMATION TREATED WITH IBRUTINIB + NIVOLUMAB IN THE PHASE 1/2A LYM1002 STUDY Anas Younes Received Received
  642-PF SYSTEMS BIOLOGY ANALYSIS OF RESPONSIVENESS OF NON-HODGKIN LYMPHOMA B-CELL LINES TO CD37 TARGETING RADIOIMMUNOTHERAPY Sebastian Patzke Received Received
  643-PF CBL-MZ IS NOT A SINGLE BIOLOGICAL ENTITY: EVIDENCE FROM GENOMIC ANALYSIS AND PROLONGED CLINICAL FOLLOW UP Jonathan Strefford Received Received
  644-PF HETEROGENEOUS MUTATIONS AT RHOA EXON 2 REVEALED BY TARGETED SEQUENCING OF CELL FREE DNA AND PERIPHERAL BLOOD MONONUCLEAR CELL DNA IN PERIPHERAL T-CELL LYMPHOMA Simon D. Wagner Received Received
  645-PF PROGRAMMED DEATH-1 PATHWAY UP-REGULATION BY LENALIDOMIDE IN ACTIVATED LOW-GRADE LYMPHOMA CELLS Fortunato Morabito Received Received
  647-PF INCORPORATION OF GENE EXPRESSION PROFILING FOR CELL-OF-ORIGIN DETERMINATION USING FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE SECTIONS IN ROUTINE WORK-UP OF DIFFUSE LARGE B-CELL LYMPHOMA CASES Ryan S. Robetorye Received Received
  648-PF DIFFUSE LARGE B CELL LYMPHOMA WITH CONCORDANT BONE MARROW INVOLVEMENT. UTILITY OF FLOW CYTOMETRY, CLINICAL AND BIOLOGICAL EVALUATION. Lucia Morais Received Received
  651-PF IMMUNOGLOBULIN KAPPA DELETING ELEMENT (IGK-KDE) REARRANGEMENTS AS POSSIBLE TARGET FOR MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN MANTLE CELL LYMPHOMA (MCL) Irene Della Starza Received Received
  652-PF CIRCULATING MICRORNAS (MIRNAS) IN ITP PATIENTS BEFORE AND AFTER TREATMENT WITH THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS)–DIAGNOSTIC AND PROGNOSTIC VALUE Lamya Garabet Received Received
  656-PF PREEMPTIVE RITUXIMAB HAS A FAVORABLE BENEFIT-RISK BALANCE IN THE PREVENTION OF LONG-TERM RELAPSES IN IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA Matthieu Jestin Received Received
  662-PF EXTENDED FOLLOW UP OF PATIENTS TREATED IN THE RITUXIMAB AS SECOND-LINE TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA – THE RITP STUDY Waleed Ghanima Received Received
  664-PF PREDICTORS OF SUCCESS FOR SPLENECTOMY IN CHILDHOOD AUTOIMMUNE CYTOPENIA Nathalie Aladjidi Received Received
  665-PF SHORT- AND LONG-TERM ELTROMBOPAG FOR THE TREATMENT OF INHERITED THROMBOCYTOPENIAS: A PHASE 2 CLINICAL TRIAL Carlo Zaninetti Received Received
  669-PF MYH9-RELATED THROMBOCYTOPENIA: FOUR NOVEL VARIANTS AFFECTING THE TAIL DOMAIN OF THE NON-MUSCLE MYOSIN HEAVY CHAIN IIA ASSOCIATE WITH A MILD CLINICAL EVOLUTION OF THE DISEASE Carlo Zaninetti Received Received
  672-PF PERFORMANCE OF THE ISTH BLEEDING ASSESSMENT TOOL IN PREDICTING THE PRESENCE OF INHERITED PLATELET FUNCTION DISORDERS Maaike Blaauwgeers Received Received
  673-PF SPLENECTOMY IN COMPARISON WITH RITUXIMAB AS A SECOND LINE TREATMENT FOR RELAPSED OR REFRACTORY ITP Ana Boban Received Received
  676-PF PREDICTIVE FACTORS FOR SUCCESSFUL SPLENECTOMY OUTCOME – SYSTEMATIC REVIEW Mirjana Mitrovic Received Received
  678-PF PLATELET COUNT EVOLUTION AS A PREDICTOR OF OUTCOME AFTER RITUXIMAB TREATMENT IN CHRONIC IMMUNE THROMBOCYTOPENIA Shixuan Wang Received Received
  680-PF LONG-TERM EFFICACY AND SAFETY OF ROMIPLOSTIM FOR TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA Sergey Semochkin Received Received
  681-PF ITP SECONDARY TO ALEMTUZUMAB-INDUCED RENAL TRANSPLANT: OUTCOME OF 31 PATIENTS Elisa Lucchini Received Received
  682-PF AN OBSERVATIONAL, NON-INTERVENTIONAL CLINICAL PRACTICE STUDY OF ROMIPLOSTIM IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) – PLATON FINAL RESULTS Georgi Mihaylov Received Received
  683-PF COMBINED/CONCOMITANT THERAPY FOR RAPID RECOVERY IN PATIENTS WITH REFRACTORY/RECURRENT IMMUNE THROMBOCYTOPENIA (ITP) AND MODERATE/SEVERE BLEEDING: AN OBSERVATIONAL STUDY Mariasanta Napolitano Received Received
  687-PF QUALITY OF LIFE IN NEWLY DIAGNOSED AND RELAPSED DANISH MULTIPLE MYELOMA PATIENTS - A NATIONAL LONGITUDINAL STUDY OF DANISH MYELOMA STUDY GROUP Lene Kongsgaard Nielsen Received Received
  688-PF A QUALITATIVE ANALYSIS OF PSYCHOLOGICAL HEALTH MEASURES IN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA AFTER BEING TREATED WITH BFM-ALL PROTOCOLS Asif Iqbal Received Received
  690-PF DETERMINANTS AND CLINICAL SIGNIFICANCE OF MUSCULOSKELETAL SYMPTOMS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE Ana Zelic Kerep Received Received
  692-PF RAPID AND COMPREHENSIVE GENOMIC CHARACTERIZATION OF HEMATOLOGICAL MALIGNANCIES USING A HYBRID-CAPTURE TARGETED SEQUENCING PANEL Michaela Gruber Received Received
  693-PF UNTANGLING HOSPITALIZATIONS IN SYSTEMIC AMYLOIDOSIS: PATIENT CHARACTERISTICS, ECONOMIC COST AND CLINICAL OUTCOMES Tiffany P. Quock Received Received
  694-PF ERECTILE DISFUNCTION IN HEMATOLOGICAL MALIGNANCIES Frosina Krstanoska Received Received
  696-PF RELEVANT REDUCTION OF POMALIDOMIDE-RELATED NEUTROPENIA BY INTENSIVE USE OF MYELOID GROWTH FACTOR MARINA SILVIA PARISI Received Received
  697-PF REAL WORLD EVIDENCE BASED COST-EFFECTIVENESS ANALYSES (CEA) OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA (CML) IN CHINA Yongping Song Received Received
  698-PF LIVING AND COPING WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A QUALITATIVE STUDY OF GREEK PATIENTS´ EXPERIENCES ON BEHALF OF ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL Aliki Xochelli Received Received
  699-PF COMPARISON OF THE PAPER-BASED AND ELECTRONIC VERSION OF A NEW PATIENT-REPORTED OUTCOME MEASURE IN HAEMATOLOGICAL MALIGNANCY FOR USE IN CLINICAL PRACTICE, HM-PRO: AN EQUIVALENCE STUDY Pushpendra Goswami Received Received
  703-PF ERN-EUROBLOODNET: THE EUROPEAN REFERENCE NETWORK IN RARE HEMATOLOGICAL DISEASES. 1ST YEAR OF IMPLEMENTATION María del Mar Mañú Pereira Received Received
  704-PF PALLIATIVE CARE INDICATION IN NON-HODGKIN´S LYMPHOMA PATIENTS: A COMPARISON TO SOLID TUMOR PATIENTS Lucia Morais Received Received
  706-PF DIAGNOSIS DISCLOSURE IN PATIENTS WITH HEMATOLOGICAL CANCERS IN INDIA Chepsy Cherian Philip Received Received
  707-PF NATIONAL EVALUATION OF QUALITY OF CARE DURING THE 5 FIRST YEARS OF LIFE FOR CHILDREN DIAGNOSED BY THE NEWBORN SICKLE CELL SCREENING PROGRAMME IN FRANCE: RESULTS OF EVADREP STUDY Isabelle Thuret Received Received
  708-PF VISUAL CORTEX CHANGES IN CHILDREN WITH SICKLE CELL DISEASE: A MULTIMODAL MRI STUDY Raffaella Colombatti Received Received
  714-PF ACCESS TO EMERGENCY DEPARTMENT AND IDENTIFICATION OF SUBJECTS WITH SICKLE CELL DISEASE AND OTHER HEMOGLOBINOPATHIES IN REFUGEES Lucia De Franceschi Received Received
  715-PF AN ANALYSIS OF PAIN CRISIS PATTERNS IN DIFFERENT GEOGRAPHIC REGIONS OF THE WORLD: ANALYSIS FROM THE CASIRE STUDY. Raffaella Colombatti Received Received
  717-PF COULD LIVER INVOLVEMENT BE EARLY DETECTED IN SICKLE CELL DISEASE? Marta Bortolotti Received Received
  718-PF SAFETY AND IMPROVED SUSTAINED RESPONSE RATES IN PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE TREATED WITH IBRUTINIB: 1-YEAR UPDATE OF A PHASE 1B/2 STUDY Edmund Waller Received Received
  719-PF SINGLE CORD BLOOD UNIT PLUS THIRD PARTY DONOR CELLS (HAPLO-CORD) TRANSPLANTATION COMPARED TO ADULT UNRELATED DONORS IN PATIENTS WITH ACUTE LEUKEMIA: A RETROSPECTIVE CASE-CONTROL STUDY Guiomar Bautista Carrascosa Received Received
  720-PF CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION AND SALVAGE ASCT IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA WITH FIRST RELAPSE AFTER UPFRONT ASCT Henrik Gregersen Received Received
  721-PF THE ROLE OF COLLATERAL RELATED DONORS IN HAPLOIDENTICAL HEMATOPOIETIC TRANSPLANTATION: A COMPARATIVE STUDY BETWEEN COLLATERAL RELATED DONORS AND PARENTAL DONORS. Xiao-Dong Mo Received Received
  722-PF EFFICACY OF BONE MARROW DERIVED MSC FOR STEROID REFRACTORY ACUTE GVHD ASSOCIATES WITH AGE AND A DEFINED MOLECULAR PROFILE OF MSC DONORS Lotte Van Der Wagen Received Received
  723-PF PROGNOSTIC INDEX FOR PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WHO UNDERWENT HEMATOPOIETIC CELL TRANSPLANTATION: A KSGCT MULTICENTER ANALYSIS Takayoshi Tachibana Received Received
  725-PF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY: INCIDENCE, PROGNOSTIC FACTORS, MORBIDITY AND MORTALITY IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION Eleni Gavriilaki Received Received
  726-PF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN THE OUTPATIENT SETTING: A SINGLE CENTER EXPERIENCE OF 924 CONSECUTIVE TRANSPLANTS Salwa Saadeh Received Received
  731-PF COMPARISON OF MOBILIZED PERIPHERAL BLOOD STEM CELLS VERSUS BONE MARROW HAPLOIDENTICAL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE: A RETROSPECTIVE STUDY OF SFGM-TC IN 176 PATIENTS Nathalie Jacque Received Received
  732-PF G-CSF/ATG-BASED REGIMEN IS SUPERIOR TO PTCY-BASED REGIMEN IN TERMS OF ENGRAFTMENT AFTER MYELOABLATIVE HAPLOIDENTICAL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES Xiao-Jun Huang Received Received
  733-PF BENDA-BEAM HIGH-DOSE THERAPY PRIOR TO AUTO-SCT IS EFFECTIVE IN RESISTANT/RELAPSED DLBCL: A PHASE II MULTICENTRIC STUDY. Giuseppe Visani Received Received
  734-PF A HIGH PRE-TREATMENT BONE MARROW CD34+/CD38- CELL BURDEN IN PATIENTS WITH MYELODYSPLASTIC SYNDROME IS A PROGNOSTIC FACTOR FOR DISEASE PROGRESSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Madlen Jentzsch Received Received
  735-PF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROME AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOID NEOPLASMS: RETROSPECTIVE STUDY OF SFGM-TC Daniel Jaimes Albornoz Received Received
  736-PF A PHASE I/II STUDY OF PEGYLATED-INTERFERON-2ALPHA FOR RELAPSED HAEMATOLOGICAL MALIGNANCY AFTER ALLOGENEIC HAEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION Andrea Henden Received Received
  737-PF OUTCOME OF MESENCHYMAL STROMAL CELL TREATMENT IN CHRONIC GVHD PREDICTED BY THYMIC FUNCTION: A PHASE II CLINICAL STUDY Erik Boberg Received Received
  738-PF IMPAIRED BONE MARROW ENDOTHELIAL PROGENITOR CELLS ARE INVOLVED IN THE PATHOGENESIS OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOTRANSPLANT Xie-Na Cao Received Received
  739-PF PHASE II PROSPECTIVE STUDY OF DIFFERENT ATG DOSING IN ADDITION TO STANDARD HAPLOIDENTICAL TRANSPLANT CONDITIONING WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) Mona Hassanein Received Received
  740-PF EXTENSIVE TELOMERE SHORTENING IN MONONUCLEAR CELLS IS ASSOCIATED WITH INFERIOR OVERALL SURVIVAL AFTER NON-MYELOABLATIVE ALLO-HCT Jens Helby Petersen Received Received
  741-PF G-CSF MOBILIZED MACROPHAGES POLARIZATION MAY PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Qi Wen Received Received
  742-PF INTERFERON-? IS EFFECTIVE FOR TREATMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH T(8;21) ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Xiao-Dong Mo Received Received
  743-PF EFFICACY AND SAFETY OF AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN ELDERLY MULTIPLE MYELOMA (MM) PATIENTS AGED = 65 YEARS: A SINGLE CENTRE EXPERIENCE Philip Campbell Received Received
  744-PF PD-1 CONTRIBUTES TO THE DEVELOPMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANTATION Eunkyoung You Received Received
  745-PF A PHASE 1 PILOT STUDY OF ULTRA-LOW DOSE IL-2 AS GVHD PROPHYLAXIS IN HAPLO-IDENTICAL STEM CELL TRANSPLANTATION Sawa Ito Received Received
  746-PF THE IMPACT OF CMV REACTIVATION ON HSCT OUTCOMES IN CHILDREN WITH MALIGNANCIES: A 13 YEARS SINGLE CENTER EXPERIENCE Francesco Baccelli Received Received
  747-PF A REAL-LIFE SINGLE CENTER RETROSPECTIVE ANALYSIS TO EVALUATE EBMT RISK INDEX AS A PROGNOSTIC FACTOR IN PEDIATRIC HSCT Alessandro Di Gangi Received Received
  749-PF THE HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX IN THE CONTEXT OF AUTOLOGOUS STEM CELL TRANSPLANTATION CAN PREDICTS CLINICAL OUTCOMES. Alexandra Martínez-Roca Received Received
  750-PF INTRA-BONE CORD BLOOD TRANSPLANT WITHOUT IN-VIVO T-CELL DEPLETION: RESULTS IN 12 PATIENTS. Elisabetta Xue Received Received
  751-PF HEMATOPOIETIC REGENERATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION WITH ACTUAL BODY WEIGHT BASED DOSING OF CONDITIONING CHEMOTHERAPY David Fuchs Received Received
  752-PF IMPACT OF MIXED CHIMERISM IN T REGULATORY CELLS ON RELAPSE RATE IN ACUTE LEUKEMIA PATIENTS AFTER ALLO-HSCT Darya Dubnyak Received Received
  753-PF REDUCED-INTENSITY CONDITIONING WITH FLUDARABINE AND BUSULFAN VERSUS FLUDARABINE AND MELPHALAN FOR T DEPLETED ALLOGENEIC TRANSPLANT IN MYELOID MALIGNANCIES: AN EXPERIENCE OF A TERTIARY CENTRE Marta Sofia Lopes Received Received
  755-PF A MESENCHYMAL STROMAL CELL (MSC)-DERIVED COMBINATION OF CXCL5 AND ANTI-CCL24 IS SYNERGISTIC AND SUPERIOR TO MSC AND CYCLOSPORINE FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE Xiubo Fan Received Received
  756-PF GENERATION OF IMMORTAL MURINE HEMATOPOIETIC STEM/PROGENITOR AND LEUKEMIC STEM CELL LINES FROM TRANSGENIC MICE Eszter Doma Received Received
  759-PF EX-VIVO GENERATED HUMAN CORD BLOOD MYELOID-DERIVED SUPPRESSOR CELLS (HCB-MDSCS) ATTENUATE MURINE CHRONIC GRAFT-VERSUS-HOST DISEASES Chang-Ki Min Received Received
  760-PF EFFICACY OF DEFIBROTIDE FOR PREVENTION AND TREATMENT OF ACUTE GRAFT-VERSUS HOST DISEASE IN A FULLY MHC-MISMATCHED MURINE MODEL OF ALLOGENEIC BONE MARROW TRANSPLANTATION David García-Bernal Received Received
  763-PF LONG-TERM LONGITUDINAL PROSPECTIVE CMR STUDY IN PATIENTS WITH THALASSEMIA MAJOR Antonella Meloni Received Received
  764-PF CEREBROVASCULAR DISEASE IN BETA-THALASSEMIA: NOT A DISEASE RELATED COMPLICATION? Immacolata Tartaglione Received Received
  766-PF DAILY ALTERNATING DEFERASIROX AND DEFERIPRONE AS NEW THERAPEUTIC SCHEME FOR IRON OVERLOAD IN UNTREATABLE TRANSFUSION DIPENDENT THALASSEMIA PATIENTS Valeria Pinto Received Received
  767-PF DENOSUMAB EFFECTS ON SERUM LEVELS OF THE BONE MORPHOGENIC PROTEINS ANTAGONIST NOGGIN IN PATIENTS WITH BETA-THALASSEMIA MAJOR AND OSTEOPOROSIS Evangelos Terpos Received Received
  769-PF COMPARAISON OF MORBIDITIES BETWEEN NON TRANSFUSION AND TRANSFUSION DEPENDENT THALASSEMIA PATIENTS OLDER THAN 45 YEARS Alessia Marcon Received Received
  770-PF A RANDOMIZED, CONTROLLED, PHASE III STUDY TO EVALUATE S-303/GLUTATHIONE PATHOGEN-INACTIVATED RED BLOOD CELLS IN THALASSEMIA MAJOR PATIENTS (SPARC) Yesim Aydinok Received Received
  771-PF EVALUATION OF VASCULAR HEALTH OF E-BETA THALASSEMIA PATIENTS: EFFECT OF IRON OVERLOAD Dibyendu De Received Received
  772-PF CHRONIC HEPATITIS C VIRUS INFECTION IN THALASSEMIA MAJOR: A NEW CARDIOVASCULAR RISK FACTOR? Antonella Meloni Received Received
  774-PF EFFICACY AND SAFETY OF RESVERATROL, AN ORAL HBF AUGMENTING AGENT, IN PATIENTS WITH BETA THALASSEMIA INTERMEDIA Mehran Karimi Received Received
  775-PF HYPERURICEMIA, URINE URIC EXCRETION AND ITS COMPLICATIONS IN THALASSEMIA PATIENTS Adisak Tantiworawit Received Received
  778-PF ANTICOAGULATION IN THE OBESE - A PROSPECTIVE REGISTRY Eva Hortas Received Received
  779-PF CHARACTERISTICS OF PLATELET COUNT AND SIZE AND DIAGNOSTIC ACCURACY OF MEAN PLATELET VOLUME IN PATIENTS WITH VENOUS THROMBOEMBOLISM. A SYSTEMATIC REVIEW AND META-ANALYSIS Houshang A. Shemirani Received Received
  781-PF SEASONAL VARIATION IN PULMONARY EMBOLISM BUT NOT DEEP VEIN THROMBOSIS INCIDENCE: A KOREAN NATIONWIDE VENOUS THROMBOEMBOLISM EPIDEMIOLOGY STUDY Junshik Hong Received Received
  783-PF TROMBOSIS IN LYMPHOMA, INCIDENCE, RISK FACTORS AND MANAGEMENT. Virginia Pradillo Received Received
  784-PF PLATELET HYPERREACTIVITY AND POSTOPERATIVE VENOUS THROMBOEMBOLISM IN KNEE REPLACEMENT ARTHROPLASTY Jimyung Kim Received Received
  785-PF THROMBOEMBOLISM IN CHILDREN WITH CANCER; A RETROSPECTIVE MULTICENTER STUDY IN KOREA Hyoung Soo Choi Received Received
  786-PF A RETROSPECTIVE ANALYSIS OF UTILISATION OF DIRECT ORAL ANTICOAGULANT LEVELS FROM A TERTIARY HAEMATOLOGY CENTRE Nicholas Denny Received Received
  787-PF LONG- TERM MANAGEMENT OF RECURRENT VENOUS THROMBOEMBOLISM IN BLOOD CANCER PATIENTS AT HIGH BLEEDING RISK. Mariasanta Napolitano Received Received
  788-PF A MULTICENTER EXPERIENCE WITH IDARUCIZUMAB "IN REAL WORLD" AS REVERSAL ANTICOAGULATION OF DABIGATRÁN Marta Villalba Montaner Received Received
  790-PF A TERTIARY INSTITUTION BLOOD BANK EXPERIENCE AFTER THE IMPLEMENTATION OF A UNIFIED NATIONAL MASSIVE TRANSFUSION PROTOCOL (MTP) IN SINGAPORE. Chun-Tsu Lee Received Received
  792-PF RED CELL TRANSFUSION THRESHOLDS IN PATIENTS RECEIVING INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA Amy Trottier Received Received
  793-PF DEVELOPMENT OF HUMANIZED MOUSE MODELS TO EVALUATE AND PREVENT MOTHER-TO-CHILD HTLV-1 TRANSMISSIONS Takuo Mizukami Received Received
  794-PF A DESCRIPTIVE STUDY OF TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI) IN THE CANARY ISLANDS. Cynthia Acosta Fleitas Received Received
  796-PF TEN YEAR EXPERIENCE OF RED BLOOD CELL TRANSFUSION ADEQUACY INDEX AS PART OF PATIENT BLOOD MANAGEMENT PROGRAM. Gustavo de Carvalho Duarte Received Received
  797-PF A 3-PART DIFF POCT CELL ANALYZER AT THE HEMATO-ONCOLOGY WARD FOR CLINICAL DECISION MAKING OF PLATELET TRANSFUSION AND CHEMOTHERAPY Nele Van den Eede Received Received
  798-PF EVALUATION OF OXYGEN TRANSPORT OF BLOOD IN PATIENTS WITH ANEMIA ON THE BACKGROUND OF THE RED BLOOD CELLS TRANSFUSIONS Nikolay Romanenko Received Received
  896-PS INFLAMED BM-MSCS HIGHLY ATTRACT TEL-AML1+ PRE-LEUKEMIC CELLS AND PROVIDE A SUSTAINING NICHE FOR THEIR EMERGENCE Linda Beneforti Received Received
  897-PS TRANSLATOME ANALYSIS REVEALS ALTERED SERINE METABOLISM IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Kim Kampen Received Received
  898-PS MIR-497~195 CLUSTER IS ASSOCIATED WITH FAVORABLE OUTCOME AND HAS A TUMOR SUPPRESSIVE FUNCTION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA Elena Boldrin Received Received
  899-PS MICRORNA-142 IS AN ESSENTIAL REGULATOR OF B CELL DEVELOPMENT AND MALIGNANT TRANSFORMATION Wei-Le Wang Received Received
  900-PS AN ESSENTIAL ROLE OF LCK IN T-ALL CELL PROLIFERATION AND SURVIVAL Yuzhe Shi Received Received
  901-PS TITLE: PROGNOSTIC IMPACT OF THE BCR/ABL1-LIKE SIGNATURE IN ADULT B-LINEAGE ALL. FIRST ANALYSIS OF THE GIMEMA LAL1913 PROTOCOL Sabina Chiaretti Received Received
  902-PS CHARACTERIZATION OF PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH DNA METHYLATION STATUS Shunsuke Kimura Received Received
  903-PS THE PHILADELPHIA-LIKE SUBTYPE IN CHILDREN WITH FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY OF THE GERMAN ALL-REZ BFM 2002 TRIAL Malwine Pogodzinski Received Received
  904-PS HUMAN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA DEVELOPS HYPOXIA-RELATED CHEMORESISTANCE THROUGH HIF1? AND MTOR PATHWAY INTERACTIONS Lucine Fahy Received Received
  905-PS METABOLOMIC ANALYSIS REVEALS CEREBROSPINAL FLUID CREATINE AND XANTHINE CONCENTRATIONS AS POTENTIAL BIOMARKERS FOR CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKAEMIA Antony Cousins Received Received
  906-PS CLONAL EVOLUTION OF ACUTE LYMPHOBLASTIC LEUKEMIA CELLS FROM DIAGNOSIS TO RELAPSE Shumaila Sayyab Received Received
  907-PS REFINED DETECTION AND PHASING OF STRUCTURAL ABERRATIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA WITH LINKED-READ WHOLE GENOME SEQUENCING Yanara Marincevic-Zuniga Received Received
  908-PS AMPLICON-BASED NGS AS A TOOL FOR THE IDENTIFICATION OF NEW MARKERS WITH POOR PROGNOSIS IN B-ALL Adrian Montaño Received Received
  909-PS EXPLORING THE GENOMIC DIVERSITY OF AYA AND ADULT HIGH-RISK B-ALL CASES BY MRNA SEQUENCING Susan L Heatley Received Received
  911-PS "TRIPLE NEGATIVE" ACUTE GENE EXPRESSION CLUSTERING IDENTIFY NEW ADULT LYMPHOBLASTIC LEUKEMIA SUBGROUPS Anna Ferrari Received Received
  912-PS MOLECULAR PROFILE REFINES THE MRD-BASED PROGNOSTIC ASSESSMENT IN ADULTS WITH PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA Jordi Ribera Received Received
  915-PS COHESIN GENES MUTATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA Grazia Fazio Received Received
  916-PS EVALUATION OF SAMPLE QUALITY AND CREATION OF DATABASES FOR FOLLOW-UP ASSESSMENT OF BLAST INFILTRATION AT DAY +15 IN CHILDHOOD B CELL ACUTE LYMPHOBLASTIC LEUKEMIA. Pablo Manresa Received Received
  918-PS PROGNOSTIC VALUE OF IKZF1 DELETIONS ON THE UKALL14 TRIAL; SIGNIFICANT ROLE OF BCR-ABL1 STATUS Rachel Mitchell Received Received
  919-PS FIRST RESULTS OF NEW GIMEMA TRIAL LAL1913 FOR ADULT PATIENTS WITH PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH- ALL) Renato Bassan Received Received
  920-PS LOW MIR-151 AND MIR-451 LEVELS IN BONE MARROW AT DIAGNOSIS IS CONFIRMED AS A PROGNOSTIC FACTOR FOR RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE AIEOP 2000 CLINICAL TRIAL Jennifer Yarden Received Received
  921-PS THE CELL SURFACE PROTEIN VANIN-2 IDENTIFIES AGGRESSIVE SUBTYPES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA Virginia Rodriguez Martinez Received Received
  922-PS NILOTINIB COMBINED WITH LOWER-INTENSITY CHEMOTHERAPY FOR FRONT-LINE TREATMENT OF YOUNGER ADULTS WITH PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): INTERIM ANALYSIS OF THE GRAAPH-2014 TRIAL Yves Chalandon Received Received
  923-PS PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AND MLL REARRANGEMENT SHOW A DISTINCTIVE EXPRESSION PATTERN OF HISTONE DEACETYLASES Nerea Vega-Garcia Received Received
  924-PS PROTEOLYTIC L-ASPARAGINASE DEGRADATION AS A MECHANISM FOR NON-ANTIBODY-RELATED DRUG INACTIVATION Justyna Walenciak Received Received
  926-PS EXTRAMEDULLARY LATE RELAPSES IN ATYPICAL SITES OF ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE STUDY OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEMATOLOGY AND ONCOLOGY (AIEOP) Giovanna Giagnuolo Received Received
  927-PS INCIDENCE AND OUTCOME OF RELAPSES IN YOUNG ADULTS (18-60 YR) WITH PH--POSITIVE ALLTREATED WITH IMATINIB, CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (PETHEMA ALLPH08 TRIAL) Josep Maria Ribera Received Received
  929-PS IDENTIFICATION OF BCR-ABL-LIKE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY REAL-TIME PCR Grigory Tsaur Received Received
  931-PS THE PROGNOSIS FOR PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WHO WERE INELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE TKI ERA. Akio Shigematsu Received Received
  933-PS ENHANCING MANAGEMENT OF PH+ ALL BY MONITORING WITH AN ANALYTICALLY VALIDATED MULTIPLEX ASSAY FOR BCR-ABL1 MINOR BREAKPOINT (E1A2) WITH HIGHLY SENSITIVE DETECTION OF 1:40,000 (0.0025% OR 4.6 LOGS) Justin Brown Received Received
  934-PS THE RISK OF DEVELOPING HEPATIC TOXICITY FROM PEGYLATED-ASPARAGINASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS HIGHLY AFFECTED BY CONCOMITANT MEDICATIONS Paola Minetto Received Received
  935-PS CELL OF ORIGIN INFLUENCES DISEASE AGGRESSIVENESS AND CHEMOTHERAPY RESISTANCE IN A MOUSE MODEL OF MLL-AF9 REARRANGED ACUTE MYELOID LEUKEMIA Chi Huu Nguyen Received Received
  936-PS PLASMA PROTEOME IN PATIENTS WITH LEUKEMIA AND LYMPHOMA REVEALS MAJOR DIFFERENCES RELATED TO HEMOSTASIS, INFLAMMATION AND STROMA Anna Eriksson Received Received
  940-PS GENOMIC CHARACTERIZATION OF DIAGNOSTIC AND REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA SAMPLES THROUGH A NEXT GENERATION SEQUENCING (NGS) PANEL OF 62 GENES Diego Carbonell Received Received
  942-PS SYNERGISTIC INHIBITORY EFFECT OF HYDROXYUREA AND DECITABINE ON THE PROLIFERATION OF AML CELLS Konstantin Byrgazov Received Received
  943-PS MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA USING MULTIPARAMETRIC FLOW CYTOMETRY IS HIGHLY PREDICTIVE OF OUTCOME Chinmayee Kakirde Received Received
  944-PS EXPRESSION OF CD25 FLUCTUATES IN THE LEUKEMIC STEM CELL POPULATION OF CD25-POSITIVE AML Yuki Kageyama Received Received
  945-PS INTEGRIN ALPHA 7 EXPRESSION IS ASSOCIATED WITH PHENOTYPE AND GROWTH OF ACUTE MYELOGENOUS LEUKEMIA Nobuhiko Kobayashi Received Received
  946-PS THE ROLE OF STAT3? IN ACUTE MYELOID LEUKEMIA Petra Aigner Received Received
  947-PS DISSECTING INTRA-TUMOR HETEROGENEITY IN ACUTE MYELOID LEUKEMIA THROUGH LEUKEMIA STEM CELL-ASSOCIATED MIRNA SIGNATURES AND SINGLE-CELL RNA TRANSCRIPTIONAL PROFILING Matteo Maria Naldini Received Received
  950-PS TARGETED THERAPY FOR AML EXPRESSING SOMATIC OR GERMLINE MUTATION IN RUNX1 Kapil Bhalla Received Received
  952-PS PHOSPHO-PROFILING LINKING AML-BIOLOGY AND RESPONSE PREDICTION IN PEDIATRIC MYELOID LEUKEMIA Michaela Prchal-Murphy Received Received
  953-PS TOWARDS IMPROVING OF SURVIVAL IN AML BY REPURPOSING EXISTING DRUGS AS NOVEL SAMHD1 INHIBITORS Nikolaos Tsesmetzis Received Received
  954-PS GENOMIC-DRIVEN AND FUNCTIONAL ALTERATIONS IN ENERGY, AMINO ACID AND LIPID METABOLISM IN ACUTE MYELOID LEUKEMIA BLASTS AND STEM PROGENITOR CELLS Giorgia Simonetti Received Received
  955-PS THE CALCIUM BINDING PROTEIN S100A8/S100A9 COMPLEX IS ASSOCIATED WITH DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA Minxia Liu Received Received
  959-PS IDENTIFICATION OF GENE COPY NUMBER ABERRATIONS AS PROGNOSTIC MARKERS OF SURVIVAL IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS BY EXOME SEQUENCING OF LEUKEMIA DNA IN THE MAYO CLINIC AML EPIDEMIOLOGY COHORT Yan Asmann Received Received
  961-PS ACUTE MYELOID LEUKEMIA INDUCED TRANSFORMATION OF THE HUMAN BONE MARROW MICROENVIRONMENT PREDICTS CLINICAL OUTCOME Yiyang Chen Received Received
  962-PS IMMUNOPHENOTYPIC PROFILING OF LEUKEMIC STEM CELLS TO TRACK FLT3-ITD POSITIVE, CHEMO-RESISTANT CLONES IN ACUTE MYELOID LEUKEMIA Tiziana Ottone Received Received
  964-PS MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG) Orietta Spinelli Received Received
  966-PS FURTHER EVIDENCE FOR GPR56, BUT NOT CLL-1 (CLEC12A) AS A MARKER FOR LEUKEMIC STEM CELLS IN CD34-POSITIVE ACUTE MYELOID LEUKEMIA Shruti Daga Received Received
  967-PS MOLECULAR ABNORMALITIES IN THERAPY-RELATED ACUTE MYELOID LEUKEMIAS Gueorgui Balatzenko Received Received
  968-PS CD123 REDIRECTED NK92 CELLS FOR ACUTE MYELOID LEUKEMIA Li Zhou Received Received
  969-PS THE DIFFERENTIAL EXPRESSION OF DNMT3A SPLICE VARIANTS AND THEIR PROGNOSTIC RELEVANCE IN ACUTE MYELOID LEUKEMIA Stefanie Beinicke Received Received
  972-PS CANDIDATE FDA-APPROVED DRUGS THAT MAY MIMIC HOXA CLUSTER DELETION IN MLL-AF9 LEUKEMIA. Laura Kettyle Received Received
  974-PS MUTATIONAL LANDSCAPE OF RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA Licia Iaccarino Received Received
  976-PS VEGFC ANTIBODY TREATMENT: A NEW DIFFERENTIATION THERAPY FOR AML Kim R. Kampen Received Received
  978-PS SINGLE CENTRE REAL-LIFE EXPERIENCE OF HYPOMETHYLATING AGENTS WITH OR WITHOUT DLI AS SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION. Davide Lazzarotto Received Received
  979-PS CONSOLIDATION CHEMOTHERAPY PREVENTS RELAPSE BY INDIRECTLY REGULATING BONE MARROW ADIPOGENESIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA Haiyan Liu Received Received
  985-PS AN EVALUATION OF CONTROL REGIMENS IN A GROUP OF HIGH RISK OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA FROM TWO COOPERATIVE GROUPS: DATA FROM THE UK NCRI AND DUTCH HOVON STUDIES Robert Hills Received Received
  986-PS TP53 ALTERATIONS AND MONOSOMAL KARYOTYPE IN OLDER UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH DECITABINE Heiko Becker Received Received
  987-PS IDENTIFYING A GENETICALLY DEFINED RISK GROUP OF PEDIATRIC AML PATIENTS THAT CANNOT BE RESCUED AT ALL AFTER THE FAILURE OF THE FIRST LINE TREATMENT Naghmeh Niktoreh Received Received
  988-PS A PHASE II STUDY OF THE AURORA A KINASE INHIBITOR ALISERTIB COMBINED WITH 73 INDUCTION CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA eva hortas Received Received
  990-PS NATIONAL EARLY WARNING SCORE (NEWS), QUICK SEQUENTIAL (SEPSIS-RELATED) ORGAN FAILURE ASSESSMENT (QSOFA) AND MICROBIOLOGICAL EVALUATION IN FEBRILE NEUTROPENIA OF ACUTE MYELOID LEUKEMIA Barbara Nicolino Received Received
  991-PS COMPARISON BETWEEN MULTIPARAMETRIC FLOW CYTOMETRY AND RT-QPCR ASSAY IN EVALUATING MINIMAL RESIDUAL DISEASE BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION IN NPM1 ACUTE MYELOID LEUKEMIA Chiara Caprioli Received Received
  992-PS MRD STATUS AT TRANSPLANTATION IN SECOND OR THIRD CR IS THE STRONGEST FACTOR AFFECTING THE PROBABILITY OF RELAPSE IN AML PATIENTS Fabio Guolo Received Received
  994-PS CELL-FREE DNA MONITORING OF MINIMAL RESIDUAL DISEASE IN AML USING A TARGETED NGS GENE PANEL Zhiyi Xie Received Received
  995-PS INTRA-PATIENT DOSE-ESCALATION STUDY OF CRENOLANIB MAINTENANCE THERAPY IN PATIENTS WITH FLT3 MUTANT AML WHO HAD UNDERGONE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) Betul Oran Received Received
  996-PS CONSOLIDATION THERAPY WITH PONATINIB IN COMBINATION WITH CYTARABINE IN PATIENTS FOR FLT3-ITD ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION. Philippe Rousselot Received Received
  999-PS CLADRIBINE ADDED TO STANDARD INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKAEMIA, 4-YEAR EXPERIENCES FROM SLOVENIA Saša Anžej Doma Received Received
  1001-PS FLUDARABINE, HIGH DOSE CYTARABINE AND IDARUBICIN-BASED INDUCTION (FLAI) IS HIGHLY EFFECTIVE IN AML WITH MUTATED NPM1 WITH CONCOMITANT FLT3-ITD MUTATION IRRESPECTIVELY OF FLT3-ITD ALLELIC BURDEN Paola Minetto Received Received
  1002-PS CLINICAL CHARACTERISTICS AND PROGNOSIS OF 34 CASES OF ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION AND MLL GENE REARRANGEMENT Jian Ouyang Received Received
  1003-PS PROGNOSTIC RELEVANCE OF FLT3, NPM1, DNMT3A, IDH1/2 GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS Ekaterina Motyko Received Received
  1004-PS IMPACT OF BCL2 AND ABCG2 OVEREXPRESSION IN ACUTE MYELOID LEUKEMIA Mario Tiribelli Received Received
  1005-PS ABSOLUTE LYMPHOCYTE COUNT RECOVERY AFTER INDUCTION REMISSION THERAPY IS A STRONG PREDICTOR OF OVERALL SURVIVAL IN ADULT ACUTE MYELOID LEUKAEMIA Joana Infante Received Received
  1006-PS TYROSINE KINASE INHIBITORS (TKI) IN RELAPSED/REFRACTORY (RR) PATIENTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) CONFER BETTER SURVIVAL THAN CHEMOTHERAPY, DUE TO A BETTER SAFETY PROFILE. Giovanni Marconi Received Received
  1007-PS ADDITION OF BORTEZOMIB TO AML-LIKE TREATMENT FOLLOWED BY NMA ALLO-SCT IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM Elisabeth Reuben Tolley Received Received
  1008-PS BLAST TRANSFORMATION IN MYELODYSPLASTIC AND MYELOPROLIFERATIVE NEOPLASMS - SIMILARITIES AND DIFFERENCES - A REVIEW OF 100 CASES Milan Jagurinoski Received Received
  1009-PS QUALITY OF LIFE IN ACUTE LEUKEMIA PATIENTS WITH COMORBID ISCHEMIC HEART DISEASE Tetiana Lymanets Received Received
  1012-PS TIME TO RELAPSE OF MANTLE CELL LYMPHOMA AFTER INTENSIVE HIGH DOSE CYTARABINE CONTAINING REGIMENS DEFINES PATIENTS RISK FOR DEATH: AN ANALYSIS FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI Carlo Visco Received Received
  1014-PS EXTRACELLULAR CIRCULATING DNA IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: BIOLOGICAL CORRELATES AND PROGNOSTIC IMPACT Dino Dujmovic Received Received
  1016-PS LENALIDOMIDE PLUS BENDAMUSTINE-RITUXIMAB DOES NOT OVERCOME THE ADVERSE IMPACT OF TP53 MUTATIONS IN MANTLE CELL LYMPHOMA Christian Winther Eskelund Received Received
  1017-PS OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) Robert Pytlik Received Received
  1018-PS WOMEN WITH DIFFUSE LARGE B CELL LYMPHOMA BENEFIT MORE FROM RITUXIMAB-CONTAINING CHEMOTHERAPY Huai-Hsuan Huang Received Received
  1019-PS HIGH RISK AGGRESSIVE B-CELL LYMPHOMAS IDENTIFIED BY FISH: A MULTICENTRIC RETROSPECTIVE STUDY FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI Maria Chiara Tisi Received Received
  1020-PS RITUXIMAB, BENDAMUSTINE AND CYTARABINE (R-BAC) IN PATIENTS WITH RELAPSED-REFRACTORY AGGRESSIVE B- CELL LYMPHOMA Maria Chiara Tisi Received Received
  1021-PS A PROPENSITY SCORE ANALYSIS SHOWS THAT RITUXIMAB DOSE-ADJUSTED EPOCH IMPROVES PROGRESSION-FREE SURVIVAL OF YOUNG PATIENTS AFFECTED BY DOUBLE EXPRESSOR DIFFUSE LARGE B -CELL LYMPHOMAS Anna Guidetti Received Received
  1024-PS EXCELLENT OUTCOMES OF OLDER PATIENTS WITH PCNSL USING R-MPV/ARA-C IMMUNOCHEMOTHERAPY WITHOUT WHOLE BRAIN RADIOTHERAPY (WBRT) Maciej Tatarczuch Received Received
  1025-PS FIRST REPORT ON A SUCCESSFUL SCREENING PROGRAM FOR MYC REARRANGEMENTS AND A PROSPECTIVE CLINICAL TRIAL BASED ON MYC REARRANGEMENT IN NEWLY DIAGNOSED DLBCL PATIENTS IN THE NETHERLANDS Martine Chamuleau Received Received
  1026-PS A NOVEL IMMUNOHISTOCHEMICAL PROGNOSTIC SCORE BASED ON MYC, BCL2 AND BCL6 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RETROSPECTIVE ANALYSIS OF DE NOVO DLBCL TREATED WITH RITUXIMAB-CHOP Mattia Novo Received Received
  1027-PS ASSESSMENT OF BONE MARROW INFILTRATION AND MINIMAL RESIDUAL DISEASE BY MULTIDIMENSIONAL FLOW CYTOMETRY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA M Baile Received Received
  1028-PS ON THE APPLICABILITY OF RHOA GLY17VAL POINT MUTATION TESTING FOR A DIFFERENTIAL DIAGNOSIS OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA Yulia Sidorova Received Received
  1029-PS THE ADDITION OF ROMIDEPSIN TO CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IS FEASIBLE IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS: RESULTS OF PHASE IB FIL-PTCL13 Annalisa Chiappella Received Received
  1031-PS GLOBAL LONGITUDINAL STRAIN (2D-GLS) IN LYMPHOMA PATIENTS TREATED WITH CHEMOTHERAPY +/- MEDIASTINAL RADIOTHERAPY: EARLY SUBCLINICAL CARDIOTOXICITY IN THE CARDIOCARE PROSPECTIVE OBSERVATIONAL STUDY. Barbara Botto Received Received
  1033-PS ARE OUTCOMES IMPROVING IN POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER? A RETROSPECTIVE ANALYSIS OF THE LAST 10 YEARS Nicholas Denny Received Received
  1035-PS COMPARISON OF R-CHOP, R-CVP, CHOP, AND CVP FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN TAIWAN: A POPULATION-BASED STUDY, 2009-2013 Huai-Hsuan Huang Received Received
  1036-PS HIGH INCIDENCE OF CARDIOMYOPATHY IN PATIENTS RECEIVING CHOEP14 - POSSIBLE SYNERGISTIC CARDIOTOXICITY OF DOSE-DENSE DOXORUBICIN AND ETOPOSIDE Igor Aurer Received Received
  1037-PS PROGNOSTIC IMPACT OF SITES OF EXTRANODAL INVOLVEMENT IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA Norihito Inoue Received Received
  1038-PS LIPOSOMAL DOXORUBICIN IN AGGRESSIVE B CELL LYMPHOMA SHOWS SIMILAR EFFICACY TO THE CONVENTIONAL FORMULATION: LONG TERM RESULTS FROM A RETROSPECTIVE COHORT STUDY Ana García-Noblejas Received Received
  1040-PS THE IMPACT OF DIFFERENT IMMUNOCHEMOTHERAPY REGIMENS ON SURVIVAL OUTCOMES IN 131 NEWLY DIAGNOSED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA Gaiane Tumian Received Received
  1043-PS AN AUDIT OF THE USE OF PROTHROMBIN COMPLEX CONCENTRATION Samantha Bonney Received Received
  1044-PS HAEMOSTATIC ABNORMALITIES OR DEFECTS IN GREEK PATIENTS WITH GAUCHER DISEASE VERONIKI KOMNINAKA Received Received
  1045-PS THALIDOMIDE USE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A RETROSPECTIVE EVALUATION OF THE PATIENTS Mehmet Baysal Received Received
  1047-PS CONGENITAL FXIII DEFICIENCY IN PAKISTAN Munira Borhany Received Received
  1048-PS DISSEMINATED INTRAVASCULAR COAGULATION SCORING IN CHILDREN WITH ACUTE LEUKEMIA: IS THERE A SIMPLER AND ECONOMICAL ALTERNATIVE? Yasmine El Chazli Received Received
  1049-PS EFFECT OF THROMBOELASTOGRAPHY DEFINED COAGULOPATHY IN TRAUMATIC BRAIN INJURY Dibyendu De Received Received
  1050-PS ASSESSMENT AT DIAGNOSIS OF 200 PATIENTS WITH A PNH CLONE OR GPI-DEFICIENT CELLS =0.01% ENROLLED IN A NATION-WIDE MULTICENTRIC PROSPECTIVE OBSERVATIONAL STUDY Magali Le Garff-Tavernier Received Received
  1051-PS ASSOCIATION OF AUTOPHAGY-RELATED GENE 5 VARIANTS WITH ACQUIRED APLASTIC ANEMIA IN HAN-CHINESE POPULATION Yahong You Received Received
  1053-PS CLINICAL EFFICACY OF THERAPIES FOR TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A RETROSPECTIVE COHORT STUDY IN MULTIPLE HOSPITALS Guangsheng He Received Received
  1054-PS IDIOPATHIC NEUTROPENIA OF INFANCY: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY Piero Farruggia Received Received
  1055-PS DYNAMICS OF CMV AND EBV LOADS AFTER IMMUNOSUPPRESSIVE TREATMENT WITH RABBIT ATG AND CYCLOSPORINE IN ADULT APLASTIC ANEMIA: A PROSPECTIVE OBSERVATIONAL STUDY Sung-Soo Park Received Received
  1057-PS SCREENING FOR TELOMERE DISEASE IS IMPORTANT TO IMPROVE THE OUTCOME OF HSCT IN PEDIATRIC PATIENTS SUFFERING FROM SEVERE APLASTIC ANEMIA. Iris Nederlof Received Received
  1058-PS RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN CONGENITAL BONE MARROW FAILURE SYNDROMES: SINGLE CENTER EXPERIENCE WITH FOCUS ON TCR ??+/CD19+ DEPLETION Zhanna Shekhovtsova Received Received
  1059-PS REACTIVATION OF HEPATITIS B VIRUS INFECTION IN APLASTIC ANEMIA PATIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPY Guangsheng He Received Received
  1060-PS ADULT PATIENTS WITH ACQUIRED PURE RED CELL APLASIA: COMBINATION OF CYCLOSPORINE A AND CORTICOSTEROIDS PRODUCE BETTER CR Guangsheng He Received Received
  1061-PS MANAGEMENT OF PATIENTS WITH SEVERE APLASTIC ANAEMIA WHO ARE REFRACTORY TO PLATELET TRANSFUSIONS USING LEUKOCYTE CONCENTRATES Jiali Huo Received Received
  1064-PS OPTIMIZING MRD RESPONSE ASSESSMENT USING HIGH-SENSITIVITY PERIPHERAL BLOOD MONITORING DURING TREATMENT WITH IBRUTINIB COMBINED WITH OBINUTUZUMAB OR VENETOCLAX IN CLL . Andy C. Rawstron Received Received
  1066-PS HIGH CD9 EXPRESSION IS ASSOCIATED WITH THE MYD88 L265P MUTATION AND REDUCED FAILURE-FREE SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA Jennifer R. Brown Received Received
  1068-PS SELECTIVE CHK1 INHIBITOR MU380 EXHIBITS SINGLE-AGENT ACTIVITY AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA CELLS WITH TP53 MUTATIONS Miroslav Boudny Received Received
  1069-PS PI3K INHIBITORS INHIBIT TUMOR MICROENVIRONMENT (TME) REGULATION OF PROGRAMMED DEATH-1 (PD1) AND PDL1/2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A POTENTIAL APPROACH TO OVERCOME TUMOR-INDUCED TOLERANCE Fortunato Morabito Received Received
  1070-PS PEMBROLIZUMAB (PEM) ACTIVITY IN CLL IS IMMUNE TO TUMOR MICROENVIRONMENTAL (TME) STIMULI Fortunato Morabito Received Received
  1071-PS DUAL MTOR KINASE INHIBITORS SYNERGIZE WITH IBRUTINIB TO INDUCE CLL APOPTOSIS, AND OVERCOME BCR- AND STROMAL-MEDIATED SURVIVAL ADVANTAGES CONFERRED IN THE MICROENVIRONMENT Michael William Moles Received Received
  1074-PS NEXT-GENERATION SEQUENCING AND CRISPR/CAS9 APPLICATION TO ELUCIDATE THE IMPLICATIONS OF TP53 MUTATIONS IN DEL(13Q) CHRONIC LYMPHOCYTIC LEUKEMIA Miguel Quijada-Álamo Received Received
  1076-PS ANALYSIS OF LOCUS-SPECIFIC LINE-1 AND ALU ELEMENT DNA METHYLATION REVEALS NOVEL EARLY EPIGENETIC CHANGES IN CHRONIC LYMPHOCYTIC LEUKAEMIA Timothy Barrow Received Received
  1078-PS DETIN: OVERCOMING TUMOR IN NORMAL CONTAMINATION. Amaro Taylor-Weiner Received Received
  1079-PS TRACKING THE MINOR CLONES IN OLIGOCLONAL CHRONIC LYMPHOCYTIC LEUKEMIA USING HIGH-THROUGHPUT IMMUNOPROFILING Kamila Stranska Received Received
  1080-PS SINGLE CELL ABNORMALITIES ON CLASSIC G-BANDING ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: A NEW DIAGNOSTIC AND BIOLOGICAL CHALLENGE? Anastasia Athanasiadou Received Received
  1081-PS HIGHER RESPONSIVENESS OF CLL CELLS TO B-CELL RECEPTOR STIMULATION IS ASSOCIATED WITH REDUCED EXPRESSION OF INHIBITORY MOLECULES OF THE NF-?B PATHWAY Ruud WJ Meijers Received Received
  1082-PS COMPARISON OF CELLULAR AND CELL-FREE DNA FOR THE DETECTION AND MONITORING OF BTK MUTATED CLL CLONES IN PATIENTS WITH SUBSEQUENT THERAPY AFTER IBRUTINIB FAILURE Wiebke Schier Received Received
  1084-PS HIGH SET ALPHA TO SET BETA ISOFORM EXPRESSION IS ASSOCIATED WITH INFERIOR OUTCOMES AND DISCRIMINATES FAVORABLE RISK IN TWO INDEPENDENT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) COHORTS Danielle Brander Received Received
  1087-PS DISTINCT DNA METHYLATION PROFILES IN DIFFERENT CYTOGENETIC SUBGROUPS OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE INTRIGUING CASE OF TRISOMY 12 Maria Tsagiopoulou Received Received
  1089-PS BIALLELIC INACTIVATION OF ATM AND BIRC3 IN DEL(11Q) CELLS DRIVES GENOMIC INSTABILITY AND TUMOR EXPANSION IN CRISPR/CAS9-GENERATED MODELS OF CHRONIC LYMPHOCYTIC LEUKEMIA Miguel Quijada-Álamo Received Received
  1090-PS MASS CYTOMETRY REVEALED LEUKEMIC MICROENVIRONMENT COMPLEXITY: IMPLICATIONS FOR IMMUNOTHERAPY IN A MOUSE MODEL OF CHRONIC LYMPHOCYTIC LEUKEMIA Etienne Moussay Received Received
  1091-PS CD20 IS A DIRECT REGULATOR OF B-CELL RECEPTOR SIGNALING IN THE MICROENVIRONMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA Gabriela Pavlasova Received Received
  1092-PS ROLE OF MTORC1 IN NORMAL HAEMOPOIESIS AND LEUKAEMOGENESIS Natasha Malik Received Received
  1093-PS FIRST-IN-CLASS ORAL TYROSINE KINASE INHIBITOR (KAN0439834) TARGETING ROR1 INDUCED SIGNIFICANT APOPTOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS Mohammad Hojjat-Farsangi Received Received
  1094-PS PROGNOSTIC IMPACT OF POSITIVE MINIMAL RESIDUAL DISEASE (MRD) BELOW THE THRESHOLD OF 0.01% IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS AFTER IMMUNOCHEMOTHERAPY: STUDY OF A DATASET FROM 3 FILO TRIALS Rémi Letestu Received Received
  1095-PS EVALUATION OF THE INCIDENCE, RISK FACTORS, AND MANAGEMENT OF HYPERTENSION IN PATIENTS RECEIVING IBRUTINIB FOR HEMATOLOGIC MALIGNANCIES Farrukh Awan Received Received
  1097-PS SPONTANEOUS CLINICAL REGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND BIOLOGIC FEATURES OF 27 NEW CASES FROM THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) INTERNATIONAL REGISTRY Ilaria Del Giudice Received Received
  1099-PS SURVIVAL CONTINUES TO INCREASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED ANALYSIS AMONG 19,131 PATIENTS DIAGNOSED IN THE NETHERLANDS BETWEEN 1989 AND 2015 Lina Van Der Straten Received Received
  1100-PS PROGNOSTICATION AND FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: A CONTEMPORARY, NATIONWIDE, POPULATION-BASED ANALYSIS AMONG 1,677 PATIENTS DIAGNOSED IN THE NETHERLANDS Lina Van Der Straten Received Received
  1101-PS "IMMUNO-FLOW-FISH": HIGH THROUGHPUT FLUORESCENCE IN SITU HYBRIDISATION OF PHENOTYPED CHRONIC LYMPHOCYTIC LEUKAEMIA BY IMAGING FLOW CYTOMETRY FOR CLINICAL APPLICATION Wendy Erber Received Received
  1102-PS EXPRESSION OF ANTIGENS INVOLVED IN THE FORMATION OF AN IMMUNOLOGICAL SYNAPSE IN CHRONIC LYMPHOCYTIC LEUKEMIA Darima Badmazhapova Received Received
  1103-PS IDENTIFICATION OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AT HIGH RISK OF INFECTION OR TREATMENT THROUGH MACHINE LEARNING ALGORITHMS Carsten U Niemann Received Received
  1105-PS T-LARGE GRANULAR LYMPHOCYTIC (T-LGL) LEUKEMIA: A LONG-TERM STUDY ON 51 PATIENTS-COULD WE CONFINE THE USE OF THE TERM "LEUKEMIA"? Xanthi Yiakoumis Received Received
  1106-PS FLOW CYTOMETRY AND PCR-BASED T-CELL CLONALITY TESTING FOR DISCRIMINATING BETWEEN REACTIVE AND NEOPLASTIC PROLIFERATION OF LARGE GRANULAR LYMPHOCYTES Natalia Chernova Received Received
  1107-PS A US BASED SURVEY: THE EXPERIENCES AND PERSPECTIVES OF 1147 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS Brian Koffman Received Received
  1108-PS CHRONIC LYMPHOCYTIC LEUKEMIA IN ICELAND: A NATION-WIDE EPIDEMIOLOGY STUDY FROM 2003 TO 2016 Hrafn Hliddal Thorvaldsson Received Received
  1109-PS ENRICHMENT OF ASXL1 PATHOGENIC VARIANTS AMONG PRIMARY REFRACTORY CML PATIENTS Kristin Ayoola Gustafsson Received Received
  1110-PS THE PIVOTAL ROLE OF INSULIN-LIKE GROWTH FACTOR PATHWAY AS A THERAPEUTIC TARGET IN ABL TYROSINE KINASE INHIBITOR RESISTANT LEUKEMIA CELLS Seiichi Okabe Received Received
  1112-PS THE UNCOVERING OF A BCR-ABL1 TYROSINE KINASE-INDEPENDENT SIGNATURE REVEALS NEW POTENTIAL THERAPEUTIC TARGETS IN CHRONIC MYELOID LEUKAEMIA STEM CELLS Eduardo Gomez-Castaneda Received Received
  1113-PS OPTIMAL TIME POINT FOR BCR-ABL1 KD MUTATION ANALYSIS IN CML PATIENTS; BASED ON 2013 ELN GUIDELINE Young Rok Do Received Received
  1115-PS WT1 ANALYSIS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS Sabrina Coluzzi Received Received
  1116-PS DIGITAL DROPLET PCR MAY BETTER IDENTIFY CANDIDATES FOR TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA REGARDLESS OF MEDIAN TREATMENT DURATION Gioia Colafigli Received Received
  1117-PS FREQUENCY OF TYPICAL AND ATYPICAL FUSION TRANSCRIPTS IN PATIENTS WITH BCR-ABL1-POSITIVE LEUKEMIAS – A SINGLE INSTITUTION STUDY Gueorgui Balatzenko Received Received
  1118-PS PATIENT-SPECIFIC BCR-ABL1 GENOMIC FUSION ANALYSIS OF MINIMAL RESIDUAL DISEASE OF CML PATIENTS ELIGIBLE FOR TKI STOPPING SIGNIFICANTLY OUTPERFORMED MRNA DETECTION EITHER BY QPCR OR DIGITAL PCR Katerina Machova Polakova Received Received
  1119-PS TREATMENT-FREE REMISSION AFTER SECOND-STOP OF IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE Sukjoong Oh Received Received
  1120-PS TWO YEARS OF THERAPY WITH MATINIB GENERICS IN CHRONIC MYELOID LEUKEMIA; A REPORT FROM THE POLISH ADULT LEUKEMIA GROUP (PALG) IMATINIB GENERICS REGISTRY Tomasz Sacha Received Received
  1121-PS MAINTENANCE THERAPY WITH DASATINIB ADMINISTRATED EVERY OTHER DAY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA Clémence Loiseau Received Received
  1122-PS PONATINIB 15 MG DAILY, COMBINING EFFICACY AND TOLERABILITY. A RETROSPECTIVE SURVEY IN ITALY. Gianni Binotto Received Received
  1124-PS CARDIOVASCULAR TOXICITY IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS IN REAL-LIFE PRACTICE. IDENTIFICATION OF RISK FACTORS AND ROLE OF PROPHYLAXIS Giovanni Caocci Received Received
  1126-PS PEG-INTERFERON ?LPHA 2B CAN IMPROVE MOLECULAR RECURRENCES IN THE TREATMENT-FREE REMISSION; A PILOT STUDY WITH 18-MONTH FOLLOW-UP Manuel Ayala Received Received
  1128-PS CHRONIC MYELOID LEUKEMIA ITALIAN MULTICENTER OBSERVATIONAL STUDY (CML-IT-MOS): ANALYSIS OF CLINICAL CHARACTERISTICS OF 1330 CML PATIENTS TREATED IN REAL-LIFE IN 66 ITALIAN CENTERS OF THE GIMEMA GROUP Eva Hortas Received Received
  1129-PS IMATINIB STOP STUDY FEASIBLE TO JAPANESE CLINICAL SETTING. Kensuke Usuki Received Received
  1132-PS DENSITY, HETEROGENEITY AND DEFORMABILITY OF RED CELLS AS MARKERS OF CLINICAL SEVERITY IN HEREDITARY SPHEROCYTOSIS Richard van Wijk Received Received
  1133-PS GAU-PED STUDY: UPDATE ON RESULTS AND LONG-TERM OUTCOME OF PATIENTS WITH GAUCHER DISEASE DIAGNOSED THROUGH A PAEDIATRIC ALGORITHM William Morello Received Received
  1136-PS COMBINED EMA-BINDING TEST AND OSMOTIC GRADIANT EKTACYTOMETRY SIGNIFICANTLY IMPROVE THE LABORATORY DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS Andreas Glenthøj Received Received
  1138-PS PREVALENCE AND CLINICAL SIGNIFICANCE OF SMALL PNH CLONES IN PATIENTS WITH PRIMARY AUTOIMMUNE HEMOLYTIC ANEMIA Bruno Fattizzo Received Received
  1140-PS THE ESTABLISHMENT OF SD RAT MODEL AND HISTOPATHOLOGICAL STUDY OF IMMUNE HEMOLYTIC DISEASE INDUCED BY ANTIBODY. Sai Yan Received Received
  1142-PS ORGAN INVOLVEMENT IN RARE HEREDITARY HEMOLYTIC ANEMIA Stephanie Van Straaten Received Received
  1143-PS SUCCESSFUL TREATMENT OF MEGALOBLASTIC ANEMIA WITH BONE MARROW MYELODYSPLASIA IN LESCH-NYHAN SYNDROME Maciej Machaczka Received Received
  1144-PS CORD BLOOD DERIVED GAMMA-DELTA T CELLS CAN BE EXPONENTIALLY EXPANDED IN VITRO TO INDUCE POTENT CYTOTOXICITY AGAINST HUMAN ACUTE MYELOID LEUKEMIA CELLS Alice Cheung Received Received
  1146-PS INTERLEUKIN-15-CULTURED DENDRITIC CELLS ENHANCE ANTI-TUMOR GAMMA DELTA T CELL FUNCTIONS THROUGH IL-15 SECRETION Heleen Van Acker Received Received
  1152-PS MTL-CEBPA, A SMALL ACTIVATING RNA FOR INTRAVENOUS ADMINISTRATION TO ENHANCE C/EBP? EXPRESSION IN PATIENTS WITH LIVER CANCER SHOWS POTENTIAL USE IN NEUTROPENIA Choon Ping Tan Received Received
  1153-PS SIGNIFICANT ARI-0001 (A3B1:CD8:4-1BB:CD3Z CAR19) CELL EXPANSION IN A PATIENT WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PRE-LYMPHOAPHERESIS IBRUTINIB ADMINISTRATION. Valentín Ortiz-Maldonado Received Received
  1155-PS THE COMBINATION OF CD19/BCMA-DIRECTED CART CELLS INDUCED THERAPEUTIC RESPONSE AND REVERSIBLE COMPARTMENTAL CYTOKINE RELEASE SYNDROME CONFINED TO CEREBRAL REGION IN A PATIENT WITH CNS MULTIPLE MYELOMA Caixia Li Received Received
  1157-PS ALLOGENEIC NK CELLS AND THEIR USE IN CLINICAL TRIALS Ludovit Bielik Received Received
  1158-PS IMMUNO-T, A MOTION COMIC EDUCATING PATIENTS AND CAREGIVERS ON HOW IMMUNOTHERAPY WORKS. Tessa Kerre Received Received
  1160-PS PROTEIN KINASE CK2 AS A NEW PLAYER IN GATA-1 REGULATION DURING ERYTHROPOIESIS Laura Quotti Tubi Received Received
  1161-PS TRANSCRIPTION FACTORS REGULATE DNA METHYLATION DYNAMICS IN HEMATOPOIETIC DEVELOPMENT Takahiro Suzuki Received Received
  1162-PS CANONICAL NOTCH SIGNALING IS DISPENSIBLE FOR ADULT STEADY-STATE AND STRESS MYELO-ERYTHROPOIESIS Sara Duarte Received Received
  1163-PS ENHANCING BONE MARROW TREPHINE BIOPSY ANALYZES: DEFINING PEDIATRIC LYMPHOID SUBPOPULATION REFEERENCE RANGES BY AUTOMATED ENUMERATION Jacques Malherbe Received Received
  1165-PS TELOMERASE TRANSCRIPTS FLOATING IN CANCER-DERIVED EXOSOMES REPROGRAM THE MICRORNA TRANSCRIPTOME PROFILE OF THE RECIPIENT CELLS Daniela Likonen Received Received
  1166-PS ALTERATIONS IN STROMAL PRECURSOR CELLS IN THE BONE MARROW OF PATIENTS WITH LEUKEMIA IN THE ONSET OF THE DISEASE AND AFTER TREATMENT Nataliya Petinati Received Received
  1167-PS LYMPHOPENIA AND RISK OF INFECTIONS AND INFECTION-RELATED DEATH IN DENMARK, 2003-2013: A PROSPECTIVE COHORT STUDY OF 98,344 INDIVIDUALS FROM THE GENERAL POPULATION Marie Warny Received Received
  1168-PS HEMATOPOIETIC EFFECTS OF A COMPOUND: SXN AGAINST MYELOSUPPRESSION Lu Ding Received Received
  1170-PS IMPACT OF SPLENECTOMY ON CD34+ BLOOD COUNT Valery Savchenko Received Received
  1173-PS NIVOLUMAB TREATMENT DISCONTINUATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY EXPERIENCE Liudmila Fedorova Received Received
  1174-PS BENDAMUSTINE IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AFTER FAILURE OR SUBOPTIMAL RESPONSES TO NIVOLUMAB THERAPY. Kirill Lepik Received Received
  1175-PS NIVOLUMAB RESTORES SENSITIVITY TO CHEMOTHERAPY IN CHEMOREFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS Eva Hortas Received Received
  1178-PS RELEVANCE OF PRE AND POST TRANSPLANT PET AND HASENCLEVER INDEX IN PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT FOR HODGKIN LYMPHOMA Siddharth Turkar Received Received
  1179-PS A REAL WORLD STUDY OF CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF HODGKIN LYMPHOMA IN MALAYSIA: A SINGLE CENTER EXPERIENCE IN A RESOURCE LIMITED SETTING Tze Shin Leong Received Received
  1180-PS PROGNOSTIC VALUE OF FDG-PET QUANTITATIVE ASSESSMENT OF TUMOR REDUCTION BY ?SUVMAX, ?TMTV AND ?TLG IN HODGKIN LYMPHOMA PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIEIC STEM CELL TRANSPLANTATION Pilar Perlaza Received Received
  1184-PS THE IMPACT OF CXCR4 MUTATION SUBTYPES IN THE RESPONSE AND PROGRESSION-FREE SURVIVAL OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB Jorge Castillo Received Received
  1187-PS CHARACTERIZAITON OF MALT LYMPHOMA WITH T(11;18): LONG-TERM FOLLOW-UP Kosuke Toyoda Received Received
  1188-PS CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): DESCRIPTION OF MAIN DISEASE FEATURES, CLINICAL COURSE AND OUTCOME IN A SERIES OF 98 CASES. Christina Kalpadakis Received Received
  1190-PS IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME Jorge Castillo Received Received
  1192-PS CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA (OAL): LONG-TERM FOLLOW-UP RESULTS FROM A SINGLE-INSTITUTION OBSERVATIONAL STUDY. Ritsuko Nakai Received Received
  1193-PS CD5-NEGATIVE MANTLE CELL LYMPHOMA: A DIAGNOSTIC CHALLENGE IN LEUKEMIC NON-NODAL CASES EXCLUSIVELY DIAGNOSED IN PERIPHERAL BLOOD Sara Montesdeoca Received Received
  1194-PS MARGINAL-ZONE LYMPHOMA WITH AND WITHOUT ASSOCIATION OF HEPATITIS C VIRUS INFECTION: CLINICAL CORRELATION AND TREATMENT RESULTS Gaiane Tumian Received Received
  1195-PS STUDY OF THE DISSEMINATION PATTERNS AND CLONAL RELATIONSHIP IN DIFFERENT SITES IN MULTI-SITED MALT LYMPHOMAS. A SINGLE CENTRE ANALYSIS. Maria Condom Received Received
  1199-PS INTESTINAL COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE PATHOGENS IN HEMATOLOGICAL PATIENTS: REAPPRAISAL OF SELECTIVE ORAL DECONTAMINATION Igor Stoma Received Received
  1200-PS PREVALENCE AND RISK FACTORS OF RESISTANT GRAM-NEGATIVE BACILLI COLONIZATION AND INFECTION IN HOSPITALIZED HAEMATOLOGICAL PATIENTS Ana Pilar Gonzalez-Rodriguez Received Received
  1201-PS PEDIATRIC INTENSIVE CARE ADMISSIONS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA Melpomeni Rompola Received Received
  1203-PS COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA (MDRB) IS ASSOCIATED WITH COMPLICATIONS AND POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) Alessandro Busca Received Received
  1206-PS EMERGING MICROBIAL RESISTANCE IN FEBRILE NEUTROPENIA- IS IT HIGH TIME TO EVALUATE QUALITY CONTROL MEASURES? Nida Anwar Received Received
  1207-PS THERAPEUTIC ADMINISTRATION OF IGM-ENRICHED IMMUNOGLOBULINS IMPROVES SURVIVAL IN HEMATOLOGICAL CANCER PATIENTS WITH SEVERE NEUTROPENIC SEPSIS Alessandra Forcina Received Received
  1208-PS TETANUS, DIPHTHERIA AND POLIO IMMUNITY AFTER CHEMOTHERAPY AND RITUXIMAB IN PATIENTS WITH LEUKEMIA AND LYMPHOMA Sigrun Einarsdottir Received Received
  1209-PS THE DIAGNOSTIC UTILITY AND SENSITIVITY OF THE XPERT® MTB/RIF ASSAY IN DIAGNOSING MYCOBACTERIUM TUBERCULOSIS IN BONE MARROW ASPIRATE SPECIMENS Nadhiya Subramony Received Received
  1210-PS CLINICAL AND MICROBIOLOGICAL PROFILE OF BLOODSTREAM INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND FEBRILE NEUTROPENIA Gustavo Mendez Received Received
  1212-PS VACCINATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS – GUIDELINE OF THE INFECTIOUS DISEASES WORKING PARTY (AGIHO) OF THE GERMAN SOCIETY FOR HEMATOLOGY AND MEDICAL ONCOLOGY (DGHO) Sibylle Mellinghoff Received Received
  1213-PS CHARACTERISTICS OF HEMATOLOGICAL PATIENTS WITH BLOOD CULTURES PROVEN SEPSIS – EXPERIENCE OF ONE CENTER Karla Misura Jakobac Received Received
  1214-PS CHARACTERISTICS AND OUTCOME OF POLYMICROBIAL BLOODSTREAM INFECTIONS (P-BSI) IN PATIENTS WITH HEMATOLOGICAL CANCER. Maria Elena Zannier Received Received
  1215-PS IS ANTIMICROBIAL PROPHYLAXIS NECESSARY FOR LYMPHOMA PATIENTS? A SINGLE CENTRE, REAL-LIFE EXPERIENCE Abdulkerim Yildiz Received Received
  1216-PS CASTLEMAN DISEASE WITH THE EXPERIENCE OVER 17 YEARS Guray Saydam Received Received
  1217-PS EFFECTIVENESS OF DIFFERENT IRON ORAL FORMULATION IN IRON DEFICIENCY ANEMIA DUE TO GASTROINTESTINAL BLEEDING: MULTICENTRIC RANDOMIZED STUDY. Giulio Giordano Received Received
  1218-PS RENAL FUNCTION IN TRANSFUSION-DEPENDENT ?-THALASSEMIA PATIENTS: A DECADE OF FOLLOW-UP AND COMPARISON BETWEEN CHELATION REGIMES Osama Tanous Received Received
  1219-PS GENETIC STUDIES REVEAL NEW MUTATIONS IN THE CP GENE IN ACERULOPLASMINEMIA PATIENTS Giacomo Marchi Received Received
  1220-PS DIAGNOSIS OF HEREDITARY HAEMATOLOGICAL DISEASES USING NEXT GENERATION SEQUENCING PANELS Mayka Sanchez Received Received
  1223-PS IRON DEFICIENCY ANAEMIA – ZINC PROTOPORPHYRIN, A SIMPLE, FAST, INEXPENSIVE DIAGNOSTIC METHOD João Silva Gomes Received Received
  1224-PS STUDY OF A MEDICO-ECONOMIC ADVANTAGE IN USING NEW PARAMETERS OF CBC-DIFF-RETIC IN THE EARLY DETECTION OF IRON DEFICIENCY FOR DIALYSIS PATIENTS** Elena Sukhacheva Received Received
  1225-PS ACERULOPLASMINAEMIA - THE EXTREMELY RARE ALSO EXISTS João Silva Gomes Received Received
  1226-PS IT TAKES A LOT OF IRON TO AVOID TRANSFUSION Magda Al-Obaidi Received Received
  1227-PS PANCREATIC IRON LOADING IN EMOGLOBINOPATHIES. Antonella Meloni Received Received
  1228-PS CHR AND %HYPO: BETTER METHODS FOR ASSESSING FUNCTIONAL IRON DEFICIENCY IN CHRONIC KIDNEY DISEASE? Laura Smith Received Received
  1231-PS EXPLORING THE LONG NON-CODING RNA TRANSCRIPTOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA Mattias Hofmans Received Received
  1235-PS MDS WITH P53 DYSFUNCTION: A NEW PROGNOSTIC AND PREDICTIVE CATEGORY. A STUDY FROM THE ITALIAN MDS CLINICAL NETWORK Marianna Rossi Received Received
  1237-PS ALTERED CARBONYLATION PATTERN IN MYELODISPLASTIC SYNDROMES Alba Rodríguez García Received Received
  1238-PS EXPRESSION LEVEL OF SPECIFIC MIRNAS BEFORE AZACITIDINE THERAPY INITIATION MAY PREDICT FUTURE EFFICACY OF THE TREATMENT IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA Michaela Dostalova Merkerova Received Received
  1239-PS MULTICENTRIC VALIDATION OF THE "MONOCYTE ASSAY" FOR CHRONIC MYELOMONOCYTIC LEUKEMIA DIAGNOSIS BY FLOW CYTOMETRY Orianne Wagner-Ballon Received Received
  1240-PS CHARACTERIZATION AND DIFFERENTIAL EFFECTS OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES Manja Wobus Received Received
  1241-PS MYELODISPLASTIC SYNDROMES: MECHANISMS INVOLVED IN THE TRANSFORMATION TO ACUTE MYELOID LEUKEMIA (AML) Francisca Hernández Mohedo Received Received
  1243-PS AUTOPHAGY IN MYELODYSPLASTIC SYNDROMES: THE ROLE OF HIF-1A/REDD1 MOLECULAR PATHWAY Ioanna Stergiou Received Received
  1245-PS SINGLE AGENT TALACOTUZUMAB IN ELDERLY HIGH-RISK MDS OR AML PATIENTS FAILING HYPOMETHYLATING AGENTS – RESULTS OF THE SAMBA STUDY BY THE EMSCO NETWORK Uwe Platzbecker Received Received
  1246-PS HYPOMETHYLATING AGENTS ASSOCIATED INFECTIONS - SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Liat Shargian-Alon Received Received
  1248-PS A SYSTEMATIC REVIEW PROVIDES LIMITED CLINICAL EVIDENCE FOR ADDITIONAL EFFICACY OF G-CSF + ESA COMPARED TO FULL-DOSE ESA ALONE IN THE TREATMENT OF ANEMIA IN PATIENTS WITH LOW-RISK MDS Lucas Affentranger Received Received
  1249-PS LOW RISK MDS WITHOUT RING SIDEROBLASTS. CLINICAL AND BIOLOGICAL CHARACTERIZATION FROM THE SPANISH GROUP OF MDS. Félix López Cadenas Received Received
  1250-PS SEROTONIN RECEPTOR TYPE 1B CONSTITUTES A THERAPEUTIC TARGET FOR MDS AND CMML. Antonia Banus Mulet Received Received
  1251-PS INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS Paolo Strati Received Received
  1252-PS FETAL HEMOGLOBIN INDUCTION DURING DECITABINE TREATMENT OF ELDERLY MDS/AML PATIENTS: A POTENTIAL DYNAMIC BIOMARKER FOR OUTCOME Julia Stomper Received Received
  1253-PS CLINICAL IMPACT ON THE THERAPEUTIC STRATEGY ADAPTED TO THE MUTATIONAL PROFILE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH DEL(5Q) Carolina Alarcón-Payer Received Received
  1254-PS CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH 5-AZACYTIDINE. RESULTS FROM THE HELLENIC 5-AZACYTIDINE REGISTRY. Panagiotis Diamantopoulos Received Received
  1256-PS PREDICTIVE FACTORS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN HIGH-RISK OLDER PATIENTS WITH MDS AND CMML UNDER HYPOMETHILATING AGENTS. LATIN-AMERICAN MDS GROUP - GLAM Marcelo Iastrebner Received Received
  1257-PS IRON SUPPORT ENHANCES ERYTHROPOIETIN EFFECTIVENESS IN REFRACTORY ANEMIA WITH HIGH RETICULOCYTE COUNT, TRANSFERRIN SATURATION BELOW 30% AND HIGH LEVEL OF ERYPTOSIS. Giulio Giordano Received Received
  1259-PS SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT Carolina Lazzarino Received Received
  1260-PS TLR4 SIGNALING DRIVES MESENCHYMAL STEM CELLS (MSC) COMMITMENT TO PROMOTE TUMOR MICROENVIRONMENT TRANSFORMATION IN MULTIPLE MYELOMA Cesarina Giallongo Received Received
  1261-PS WHOLE EXOME SEQUENCING OF SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS Isabel Cuenca Received Received
  1263-PS A HIGH LEVEL OF GENOMIC COMPLEXITY CORRELATES WITH ADVANCED PLASMA CELL DIFFERENTIATION STAGES IN NEWLY DIAGNOSED MM PATIENTS Marina Martello Received Received
  1265-PS SYSTEMATIC IDENTIFICATION OF PHARMACOGENOMICS INTERACTIONS MODULATING DRUG RESPONSES IN MULTIPLE MYELOMA Muntasir Mamun Majumder Received Received
  1266-PS ADAR1-MEDIATED-NEIL1 EDITING IS OF BIOLOGICAL SIGNIFICANCE IN MULTIPLE MYELOMA Phaik Ju Teoh Received Received
  1267-PS DETECTION OF MYD88 AND CXCR4 MUTATIONS IN CELL-FREE DNA OF PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES Tina Bagratuni Received Received
  1268-PS NEXT-GENERATION SEQUENCING ALTERNATIVES FOR THE DETECTION AND QUANTIFICATION OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS Alejandro Medina Received Received
  1270-PS BONE MARROW MACROPHAGES IN PATIENTS WITH MULTIPLE MYELOMA IN COMPLETE REMISSION RETAIN PRO-TUMOR M2 PHENOTYPE Ester Lozano Received Received
  1271-PS PTC-028 DEMONSTRATES POTENT PRE-CLINICAL ACTIVITY AND PROVIDES A NOVEL OPPORTUNITY TO MODULATE BMI1 IN MULTIPLE MYELOMA Heinz Ludwig Received Received
  1272-PS ARGININE DEPRIVATION SUSTAINS PLASMA CELL FITNESS AND BIOENERGETICS IN MULTIPLE MYELOMA Alessandra Romano Received Received
  1273-PS DEMETHYLATION SENSITISES T(4;14) MULTIPLE MYELOMA TO RAS-MAPK PATHWAY INHIBITION Jay Hocking Received Received
  1274-PS CD96 (TACTILE) NEGATIVELY REGULATES THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA Michael O´Dwyer Received Received
  1275-PS GLUTAMINE-DEPENDENCE TARGETING BY ASPARAGINASE SIGNIFICANTLY INCREASES ANTI-MM ACTIVITY OF PROTEASOME INHIBITION Paola Minetto Received Received
  1276-PS MITOCHONDRIAL ACTIVITY PLAYS A CRITICAL ROLE IN MULTIPLE MYELOMA RESISTANCE Alejandra Ortiz Received Received
  1278-PS CARFILZOMIB-INDUCED CARDIOTOXICITY: MOLECULAR MECHANISMS AND THE EMERGING ROLE OF METFORMIN AS A PROPHYLACTIC THERAPY Evangelos Terpos Received Received
  1279-PS JAGGED1/2 INHIBITION PROMOTES TUMOR CELLS RESPONSE TO BORTEZOMIB IN A ZEBRAFISH MODEL OF MULTIPLE MYELOMA Michela Colombo Received Received
  1281-PS MULTIPLE MYELOMA: SINGLE PLARFORM ABSOLUTE COUNT OF CIRCULATING PLASMA CELLS AT DIAGNOSIS CORRELATE WITH POOR PROGNOSIS PARAMETERS. Vittorio Emanuele Muccio Received Received
  1282-PS MULTIPLE MYELOMA PATHOGENESIS: THE ROLE OF JUNB IN BONE MARROW ANGIOGENESIS Stefano Malvestiti Received Received
  1284-PS WNT/?-CATENIN AND HEDGEHOG INHIBITORS AS THERAPEUTIC APPROACHES IN B-CELL NEOPLASMS Ana Bela Sarmento Ribeiro Received Received
  1285-PS MULTIPLE MYELOMA INDUCES CHANGES IN BONE MARROW ADIPOCYTES IN VITRO AND IN VIVO Michaela Reagan Received Received
  1286-PS PROTEIN KINASE CK1 ALPHA MODULATES PROSURVIVAL AUTOPHAGY IN MULTIPLE MYELOMA Marilena Carrino Received Received
  1287-PS SERUM LIPID METABOLOMICS AS AN USEFUL BIOMARKER PREDICTING FOR THE EFFICACY OF BORTEZOMIB TREATMENT AND PERIPHERAL NEUROPATHY IN PATIENTS WITH MULTIPLE MYELOMA Masaki Ri Received Received
  1288-PS CIRCULATING SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS REFLECTS RENAL FUNCTION IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TREATED WITH BORTEZOMIB-BASED THERAPY Evangelos Terpos Received Received
  1289-PS PAN-ANTI-FGF-BASED THERAPY AS A NOVEL THERAPEUTIC INTERVENTION IN WALDENSTROM´S MACROGLOBULINEMIA Antonio Sacco Received Received
  1290-PS EVALUATION OF THE ACTIVITY OF IMIDS IN MM PROLIFERATING CELLS Joan Ballesteros Received Received
  1293-PS DOUBLET VS TRIPLET LENALIDOMIDE-CONTAINING REGIMENS FOLLOWED BY MAINTENANCE: SUBGROUP ANALYSIS BY FRAILTY STATUS AFTER A MEDIAN FOLLOW-UP OF 5 YEARS (EMN01 PHASE III STUDY) Sara Bringhen Received Received
  1295-PS SKY92 RISK STRATIFICATION AT RELAPSE PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR STANDARD-RISK MULTIPLE MYELOMA PATIENTS Rowan Kuiper Received Received
  1296-PS CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY RESULT OF SGHMM1 TRIAL, HIGH-RISK COHORT (NCT02217163) Chandramouli Nagarajan Received Received
  1299-PS LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS. Francesca Gay Received Received
  1301-PS TREATMENT AND SURVIVAL OF PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA: A NATIONWIDE POPULATION-BASED STUDY AMONG 179 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 1989 TO 2015 Mirian Brink Received Received
  1303-PS REAL WORLD CLINICAL IMPLICATIONS OF THE LIMITATIONS ASSOCIATED WITH THE REVISED INTERNATIONAL STAGING SYSTEM: UNSELECTED PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NOVEL AGENTS IN AGEING SOCIETY Yoshiaki Abe Received Received
  1304-PS EVALUATION OF MINIMAL RESIDUAL DISEASE USING NEXT GENERATION FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS Ioannis Kostopoulos Received Received
  1305-PS EARLY LIGHT CHAIN KINETICS AND DEPTH/DURATION OF HEMATOLOGIC RESPONSES TO DARATUMUMAB IN PREVIOUSLY TREATED LIGHT CHAIN AMYLOIDOSIS Gregory Kaufman Received Received
  1306-PS EFFICACY AND TOLERABILITY OF DARATUMUMAB AFTER ALLOGENEIC TRANSPLANTATION FOR HEAVILY TREATED MULTIPLE MYELOMA. Ana Pilar Gonzalez-Rodriguez Received Received
  1308-PS COMPLETE RESPONSE AND INDUCTION TREATMENT DOES NOT AFFECT SURVIVAL IN MYELOMA PATIENTS RELAPSING WITHIN 18 MONTHS FOLLOWING UP-FRONT HDM-ASCT. A POPULATION-BASED STUDY FROM 1994 TO 2015 Annette Vangsted Received Received
  1311-PS SERIAL SERUM FREE LIGHT CHAIN ASSAY CAN REDUCE THE NEED FOR 24-HOUR URINE PROTEIN ASSESSMENT FOR RESPONSE ASSESSMENT IN MULTIPLE MYELOMA Marcella Tschautscher Received Received
  1314-PS BONE MARROW PLASMA CELL INFILTRATION IN LIGHT-CHAIN AMYLOIDOSIS: IMPACT ON ORGAN INVOLVEMENT AND OUTCOME Luis Gerardo Rodríguez-Lobato Received Received
  1315-PS TREATMENT OF IGM-ASSOCIATED SYSTEMIC AL AMYLOIDOSIS WITH RITUXIMAB-BENDAMUSTINE Richa Manwani Received Received
  1316-PS TANDEM TRANSPLANTATION OVERCOMES POOR PROGNOSIS IN NEWLY DIAGNOSED EXTRAMEDULLARY MYELOMA WITH HIGH-RISK CYTOGENETICS: A RETROSPECTIVE STUDY BY THE CMWP-EBMT Nico Gagelmann Received Received
  1319-PS DISEASE ASSESSMENT BY PET-CT PLUS FLOW CYTOMETRY IN MULTIPLE MYELOMA IDENTIFIES PATIENTS WITH DIFFERENT SURVIVAL OUTCOMES Rafael Alonso Fernández Received Received
  1321-PS IXAZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE FOR INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Heinz Ludwig Received Received
  1323-PS THE MAJORITY OF NEWLY DIAGNOSED MYELOMA PATIENTS DO NOT FULFIL THE INCLUSION CRITERIA IN CLINICAL PHASE III TRIALS Tobias Wirenfeldt Klausen Received Received
  1324-PS COMPARISON OF LYMPHOTRACK® MISEQ® ASSAYS AND FLOW CYTOMETRY FOR CLONALITY AND MINIMUM RESIDUAL DISEASE ASSESSMENT IN MULTIPLE MYELOMA Ying Huang Received Received
  1325-PS QUALITY OF HEMATOLOGIC RESPONSE BUT NOT DEPTH OF NT-PROBNP RESPONSE IMPROVES SURVIVAL OF PATIENTS WITH AL AMYLOIDOSIS WHO ACHIEVE CARDIAC RESPONSE Paolo Milani Received Received
  1326-PS SUSTAINED MRD NEGATIVITY AT 12 MONTHS POST-ASCT PREDICTS OUTCOMES FOR MYELOMA PATIENTS: A REAL WORLD STUDY. Michael Austin Received Received
  1327-PS MULTIPLE MYELOMA IN PATIENTS UNDER 40 YEARS OLD: A RETROSPECTIVE ANALYSIS FROM THE INTERGOUPE FRANCOPHONE DU MYELOME (IFM). Alexis Caulier Received Received
  1328-PS AMPLICON NEXT-GENERATION SEQUENCING (NGS) OF REARRANGED IMMUNOGLOBULIN (IG) LOCI IS ADVANTAGEOUS FOR CLONAL MARKER IDENTIFICATION AND MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN MULTIPLE MYELOMA (MM). Michaela Kotrova Received Received
  1330-PS A REAL WORLD RETROSPECTIVE ANALYSIS OF EXTRAMEDULLARY DISEASE FROM BALKAN MYELOMA STUDY GROUP AND BARCELONA UNIVERSITY: CLINICAL FEATURES AND OUTCOME Meral Beksac Received Received
  1332-PS COMPARABLE OUTCOMES USING PROPYLENE GLYCOL-FREE MELPHALAN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Kevin Miller Received Received
  1335-PS ASYMPTOMATIC HEART INVOLVEMENT IN AL AMYLOIDOSIS Marco Basset Received Received
  1336-PS RANDOMIZED CLINICAL TRIAL (RCT) REPRESENTATIVENESS & OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REAL WORLD (RW) PATIENTS: COMPARISON OF ASPIRE, TOURMALINE-MM1, POLLUX, & ELOQUENT RCTS Ajai Chari Received Received
  1338-PS A PHASE II STUDY OF SELINEXOR(KPT-330) COMBINED WITH BORTEZOMIB AND DEXAMETHASONE (SVD) FOR INDUCTION AND CONSOLIDATION FOR PATIENTS WITH PROGRESSIVE OR REFRACTORY MULTIPLE MYELOMA: THE SELVEDEX TRIAL Annemiek Broijl Received Received
  1339-PS LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Qaiser Bashir Received Received
  1340-PS THE SCREENING OF PROTEINS SIGNATURES WITH SIGNALING PATHWAY IN POLYCYTHEMIA VERA AND INHIBITION OF PIM ENHANCES JAK2 INHIBITOR SENSITIVITY Wuhan Hui Received Received
  1341-PS IMPACT OF MOLECULAR ANALYSIS ON PROGNOSTIC SCORES IN ESSENTIAL THROMBOCYTHEMIA: A SINGLE CENTER PROSPECTIVE COHORT EXPERIENCE Damien Luque Paz Received Received
  1342-PS THE ROLE OF THE THROMBOPOIETIN RECEPTOR (MPL) IN MYELOPROLIFERATIVE NEOPLASMS Kira Behrens Received Received
  1344-PS PHARMACOLOGICAL INHIBITION OF IGF1R/IRS TARGETING STAT3/STAT5 SIGNALING HAS ANTI-NEOPLASTIC EFFECTS IN JAK2 V617F MYELOPROLIFERATIVE NEOPLASMS Jaqueline Cristina Fernandes Received Received
  1346-PS POLO-LIKE KINASE-1, AURORA KINASE A AND WEE1: NEW THERAPEUTIC TARGETS IN SYSTEMIC MASTOCYTOSIS Manuela Mancini Received Received
  1347-PS NLR AS SURROGATE OF MYELOID IMMUNE SUPPRESSION CAN PREDICT EARLY SPLENIC RESPONSE TO RUXOLITINIB IN MYELOFIBROSIS Alfio Bonanno Received Received
  1348-PS POSSIBLE SOMATIC MOSAICISM OF THE JAK2 GENE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS Naoki Mori Received Received
  1349-PS MULTICENTER SURVEY ON MANAGEMENT AND OUTCOME OF A RARE HEMATOLOGIC DISEASE: ADULT ONSET HISTIOCYTOSES. Davide Lazzarotto Received Received
  1351-PS DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER EXPERIENCE OF THE RETE EMATOLOGICA LOMBARDA (IRON-M STUDY) Elena Maria Elli Received Received
  1352-PS MYELOID AND LYMPHOID NEOPLASMS ASSOCIATED WITH PDGFRA AND PDGFRB REARRANGEMENTS: CLINICAL CORRELATES AND SURVIVAL OUTCOMES. Abhishek Mangaonkar Received Received
  1353-PS ASSESSING SERUM ALBUMIN CONCENTRATION, LYMPHOCYTE COUNT AND PROGNOSTIC NUTRITIONAL INDEX MIGHT IMPROVE PROGNOSTICATION IN PATIENTS WITH MYELOFIBROSIS Marko Lucijanic Received Received
  1354-PS LONG-TERM OUTCOME OF PATIENTS WITHS PLANCHNIC VEIN THROMBOSIS AND MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER EXPERIENCE Danijela Lekovic Received Received
  1355-PS GENDER EFFECT ON PHENOTYPE AND GENOTYPE IN PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: RESULTS FROM THE MYSEC PROJECT Daniela Barraco Received Received
  1356-PS TARGETED TREATMENT WITH DIVERSE TYROSINE KINASE INHIBITORS IN PATIENTS WITH PCM1-JAK2, BCR-JAK2 AND ETV6-ABL1 POSITIVE EOSINOPHILIA-ASSOCIATED MYELOID/LYMPHOID NEOPLASMS Georgia Metzgeroth Received Received
  1359-PS LIMITATIONS OF PREVIOUS PROGNOSTIC MODELS FOR THROMBOSIS AND EXPLORATION OF MODIFIED MODELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA Yoshinori Hashimoto Received Received
  1360-PS SERVICE EVALUATION OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM AND SPLANCHNIC VEIN THROMBOSIS (MPN-SVT). Sarah Wharin Received Received
  1361-PS FAMILIAL MYELOPROLIFERATIVE NEOPLASMS: A SINGLE-INSTITUTION ANALYSIS OF 22 FAMILIES Margherita Maffioli Received Received
  1362-PS THROMBOEMBOLIC EVENTS AFTER DIAGNOSIS OF POLYCYTHAEMIA VERA IN A SINGLE CENTER POPULATION Natalia Curto-Garcia Received Received
  1363-PS MIPSS70 AND TRANSFUSION DEPENDENCE PREDICT SURVIVAL IN MYELOFIBROSIS PATIENTS TREATED WITH JAK1/2 INHIBITOR THERAPY Caroline Mcnamara Received Received
  1364-PS JAK2 ALLELIC RATIO PREDICT HIGHER TROMBOTIC RISK IN MYELOFIBROSIS PATIENTS. A SINGLE CENTER EXPERIENCE ON 143 PATIENTS. Mirko Farina Received Received
  1366-PS THE "MYMPN" PATIENT REGISTRY: VALIDATION OF A PROSPECTIVE MYELOPROLIFERATIVE NEOPLASM PATIENT REGISTRY Robyn Scherber Received Received
  1367-PS THE RELATIONSHIP OF BODY MASS INDEX TO SYMPTOM BURDEN IN THE MYELOPROLIFERATIVE NEOPLASMS Robyn Scherber Received Received
  1368-PS MANAGEMENT AND OUTCOME OF PATIENTS DIAGNOSED WITH POLYCYTHEMIA VERA IN YOUNG AGE Giulia Bogoni Received Received
  1370-PS TREATMENT STRATEGIES FOR POLYCYTHEMIA VERA: OBSERVATIONS IN A DUTCH ´REAL-WORLD´ COHORT STUDY Peter Westerweel Received Received
  1371-PS PREGNANCY OUTCOMES IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – PALG (POLISH ADULT LEUKEMIA GROUP) A RETROSPECTIVE ANALYSIS Bozena Sokolowska Received Received
  1372-PS SECOND MALIGNANCIES IN HIDROXYUREA AND INTERFERON TREATED PATIENTS Telma Nascimento Received Received
  1373-PS CORRELATIONS BETWEEN GENETIC AND CLINICAL CHARACTERISTICS IN PATIENTS WITH PRIMARY MYELOFIBROSIS Liubov Polushkina Received Received
  1374-PS MUTATIONAL PROFILES OF CLASSIC MYELOPROLIFERATIVE NEOPLASMS IN TAIWANESE PATIENTS: FREQUENCY AND CLINICAL CORRELATION Huan-Chau Lin Received Received
  1376-PS CYCLIN D1-MEDIATED GENE EXPRESSION DYSREGULATION IMPACTS MANTLE CELL LYMPHOMA PATHOGENESIS Santiago Demajo Received Received
  1377-PS SPLENIC MARGINAL ZONE B-CELL LYMPHOMAS DEPENDS ON PROGRAMMED DEATH-LIGAND 1 FOR CLONAL EMERGENCE AND ARE CONTROLLED BY T-CELLS FOR PROLIFERATION RATE Nathalie Faumont Received Received
  1378-PS TPL2 KINASE HAS A TUMOR SUPPRESSIVE ROLE IN MYC-INDUCED LYMPHOMAGENESIS Elias Stagakis Received Received
  1381-PS THE NOVEL TUMOR SUPPRESSOR SAMHD1 IS FREQUENTLY DOWNREGULATED AND CORRELATES WITH GERMINAL CENTER PHENOTYPE IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) Ioanna Xagoraris Received Received
  1382-PS DUAL TARGETING OF BRD4 BY AZD5153 AND BCL2 BY AZD4320 FOR HIGH-RISK B-CELL LYMPHOMAS CONCOMITANTLY OVEREXPRESSING C-MYC AND BCL2 Tomoko Shimomura Takimoto Received Received
  1385-PS PD1-TIM3+ CELLS ARE THE PREDOMINANT POPULATION OF EXHAUSTED CD8+ CELLS IN FOLLICULAR LYMPHOMA WITH HIGH REACTIVATION POTENTIAL Theodora Anagnostou Received Received
  1386-PS ENZYME-FREE DIGITAL COUNTING OF ENDOGENOUS CIRCULAR RNA MOLECULES IN FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES FROM PATIENTS WITH B-CELL MALIGNANCIES Mette Dahl Received Received
  1387-PS PROTEIN KINASE CK1 ?LPHA SUSTAINS MANTLE CELL LYMPHOMA SURVIVAL BY IMPINGING ON BCR-LINKED SIGNALING PATHWAYS Sabrina Manni Received Received
  1388-PS WEE1 INHIBITION ENHANCES ANTI-APOPTOTIC DEPENDENCY OF DIFFUSE LARGE B-CELL LYMPHOMA CAUSED BY CELL CYCLE ARREST AND DNA DAMAGE INDUCTION Mathilde De Jong Received Received
  1389-PS INFLUENCE OF PLASMA EBV LOAD ON PROGNOSIS OF HIV-RELATED LYMPHOMAS Josep Muncunill Received Received
  1390-PS NUCLEOLIN ENHANCED ADRIAMYCIN RESISTANCE VIA THE REGULATION OF BCL-2 EXPRESSION IN CA46 BURKITT´S LYMPHOMA CELLS Jianda Hu Received Received
  1391-PS DOMINANT CYTOTOXIC NK CELL SUBSET WITHIN CLPD-NK PATIENTS IDENTIFIES A MORE AGGRESSIVE NK CELL PROLIFERATION Gregorio Barila´ Received Received
  1392-PS IDENTIFICATION OF A MIR-146B-FASL AXIS IN THE DEVELOPMENT OF NEUTROPENIA IN T-LARGE GRANULAR LYMPHOCYTES LEUKEMIA Giulia Calabretto Received Received
  1394-PS IN-SILICO DISSECTION OF DIFFUSE LARGE B CELL LYMPHOMA MICROENVIRONMENT PROVIDES A 45-GENE PANEL FOR RISK STRATIFICATION Sabino Ciavarella Received Received
  1395-PS GENOMIC CHARACTERISATION OF CIRCULATING TUMOUR DNA (CTDNA) PREFERENTIALLY IDENTIFIES EARLY CLINICALLY RELEVANT GENOMIC EVENTS AND PROVIDES INSIGHT INTO THE CLONAL ARCHITECTURE OF LYMPHOID MALIGNANCY Piers Blombery Received Received
  1397-PS MYD88 CONSTITUTIVE ACTIVATION IS DIRECTLY ABLE TO INDUCE INDOLENT LYMPHOPLASMACYTIC LYMPHOMA WITH MONOCLONAL IGM PEAK SECRETION IN 1 YEAR OLD MICE: A MODEL FOR WALDENSTROM´S MACROGLOBULINEMIA Christelle Vincent-Fabert Received Received
  1398-PS CELL OF ORIGIN AND GENOMIC PROFILE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA DETERMINED USING THE NANOSTRING LST ASSAY AND ULTRA DEEP TARGETED NEXT GENERATION SEQUENCING Csaba Bödör Received Received
  1400-PS INSUFFICIENT RECEPTOR EDITING LEADS TO DEFECTIVE B CELL CENTRAL TOLERANCE IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) Zi Sheng Received Received
  1403-PS PREDICTIVE FACTORS FOR DEVELOPING SYSTEMIC LUPUS ERYTHEMATOSUS AFTER CHILDHOOD AUTOIMMUNE CYTOPENIA Nathalie Aladjidi Received Received
  1404-PS THE POLYMORPHISM OF CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 9 GENE MAY CONTRIBUTE TO RISK OF IMMUNE THROMBOCYTOPENIA Zi Sheng Received Received
  1405-PS LABORATORY CHARACTERIZATION OF PATIENTS WITH (SUSPECTED) INHERITED PLATELET DISORDERS: RESULTS FROM THE ´THROMBOCYTOPATHY IN THE NETHERLANDS´ STUDY Maaike Blaauwgeers Received Received
  1407-PS ATRA CORRECTS IMPAIRED MACROPHAGE FUNCTION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA THROUGH A20/NLRP3 SIGNALING PATHWAY Yun He Received Received
  1408-PS RH-TPO RESTORES MEGAKARYOCYTES AND BONE MARROW NICHE COMPONENTS IN THE TREATMENT OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CIRRHOSIS ASSOCIATED WITH HEPATITIS B Wan-Yi Zhai Received Received
  1409-PS A HIGH-THROUGHPUT SCREENING ASSAY TO EVALUATE CHEMOTHERAPY-INDUCED MYELOSUPPRESSION USING HEALTHY PERIPHERAL BLOOD AND BONE MARROW Komal Kumar Javarappa Received Received
  1413-PS INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM IN EGYPTIAN CHILDREN AND ADOLESCENTS WITH IMMUNE THROMBOCYTOPENIA: ASSOCIATION WITH DISEASE SUSCEPTIBILITY, RESPONSE TO THERAPY AND OUTCOME Mohammed Mostafa Al-Tawil Received Received
  1414-PS CLINICAL CHARACTERISTICS AND TREATMENT COURSES FOR CYTOMEGALOVIRUS-ASSOCIATED THROMBOCYTOPENIA IN IMMUNOCOMPETENT CHILDREN AFTER NEONATAL PERIOD Ye Jee Shim Received Received
  1415-PS RAISED EXPRESSION OF APRIL IN THE PLATELET WITH IMMUNE THROMBOCYTOPENIA AND ITS CLINICAL IMPLICATIONS yunfeng Hao Received Received
  1416-PS EVALUATION OF HIT SYNDROME WITH AN AUTOMATED IMMUNOASSAY IN CORRELATION WITH THE 4T SCORE IN CARDIOVASCULAR PATIENTS Theoni Kanellopoulou Received Received
  1417-PS IMMATURE PLATELET FRACTION AS A MARKER OF THROMBOPOIESIS IN THROMBOCYTOPENIC PATIENTS Mario Farrugia Received Received
  1419-PS CHANGES IN PLATELET AGGREGATION DURING PREGNANCY AND THE IMMEDIATE POSTPARTUM PERIOD Brwa Hussein Received Received
  1421-PS THE IMPACT OF HIGH MOBILITY GROUP BOX 1 IN THE PATHOGENESIS OF IMMUNE THROMBOCYTOPENIA Mehmet Baysal Received Received
  1422-PS WHAT ARE THE UNDERLYING CAUSES AND CLINICAL CHARACTERISTICS OF CHILDREN WITH REACTIVE THROMBOCYTOSIS AT A KOREAN TERTIARY MEDICAL CENTER? Ye Jee Shim Received Received
  1424-PS STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL PATIENTS DURING THE FIRST YEAR OF IBRUTINIB TREATMENT Bozena Sokolowska Received Received
  1425-PS VALIDATION OF THE PLASMIC SCORE FOR THROMBOTIC MICROANGIOPATIES IN A SINGLE UNVERSITY HOSPITAL Maria Del Carmen Ballester Received Received
  1430-PS IMPROVABLE LIFESTYLE FACTORS IN LYMPHOMA SURVIVORS Carla Minoia Received Received
  1433-PS THE ROLE OF MENTAL AND BEHAVIORAL DISORDERS IN LEUKEMIA PREDISPOSITION: A NATIONWIDE CASE-CONTROL STUDY Hanna Moisander-Joyce Received Received
  1435-PS QUALITY OF LIFE IN PATIENTS WITH RARE HEREDITARY HEMOLYTIC ANEMIA, THE IMPORTANCE OF SOCIAL SUPPORT Stephanie Van Straaten Received Received
  1436-PS HOW PHYSICIANS´ AND PATIENTS´ CHARACTERISTICS AFFECT THE LENGTH OF PATIENTS´ VISIT IN THE HEMATO-ONCOLOGICAL CLINIC. Irina Amitai Received Received
  1439-PS NO ASSOCIATION BETWEEN INDOOR RADON AND CHILDHOOD LEUKEMIA IN FRECCLE (FINNISH REGISTER-BASED CASE-CONTROL STUDY OF CHILDHOOD LEUKEMIA) Atte Nikkilä Received Received
  1440-PS CLARITHROMYCIN ADDED TO THE VCD REGIMEN CAUSES REDUCED HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS Lene Kongsgaard Nielsen Received Received
  1441-PS RELINF PROJECT: PROSPECTIVE EPIDEMIOLOGICAL REGISTRY OF LYMPHOID NEOPLASMS IN SPAIN, ON BEHALF OF GELTAMO GROUP Mariana Bastos Oreiro Received Received
  1444-PS HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PEDIATRIC PATIENTS WITH RED CELL PYRUVATE KINASE DEFICIENCY Paraskevi Klothaki Received Received
  1445-PS QUALITY OF LIFE IS REDUCED IN PATIENTS WITH (SUSPECTED) PLATELET FUNCTION DISORDERS Maaike Blaauwgeers Received Received
  1446-PS PALLIATIVE CARE INDICATION IN ONCOHEMATOLOGIC PATIENTS: A COMPARISON TO SOLID TUMOR PATIENTS Lucia Morais Received Received
  1448-PS EFFICACY AND SAFETY OF FACILITATED SUBCUTANEOUS IGG ADMINISTRATION IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DUE TO HEMATOLOGICAL MALIGNANCIES. A SINGLE-CENTER RETROSPECTIVE ANALYSIS. Maria Dimou Received Received
  1449-PS IMPACT OF LOW GRADE ADVERSE EVENTS OF TYROSINE KINASE INHIBITORS ON THE QUALITY OF LIFE OF PATIENTS TREATED FOR CHRONIC MYELOID LEUKEMIA Benlazar Sidi Mohamed El Amine Received Received
  1450-PS HEME-INDUCIBLE LIPID OXIDATION PATTERN SUPPORTS MONITORING OF CELL-FREE HEMOGLOBIN ACTIVITY IN PATIENTS WITH SICKLE CELL DISEASE. Jeremy Deuel Received Received
  1452-PS THE OXYGENSCAN: CONTINUOUS MEASUREMENT AND QUANTIFICATION OF SICKLING DURING DE- AND REOXYGENATION TO MONITOR DISEASE SEVERITY AND TREATMENT EFFECT IN SICKLE CELL DISEASE. Eva Hortas Received Received
  1454-PS EARLY RECOGNITION OF THE SICKLING PROCESS OF ERYTHROCYTES BY LABEL-FREE LIGHT MICROSCOPIC IMAGING IN PATIENTS WITH SICKLE CELL DISEASE Irene Metze Received Received
  1456-PS IMPROVEMENT OF THE MULTIDISCIPLINARY MANAGEMENT OF SICKLE CELL DISEASE PATIENTS: IMPLEMENTATION OF A SICKLE CELL DISEASE PATIENT´S CLINICAL DATABASE: BELGIAN REGISTER OF SICKLE CELL DISEASE PATIENTS Beatrice Gulbis Received Received
  1458-PS CORRELATION BETWEEN HEMOLYSIS AND HYPERCOAGULABILITY MARKERS AND EFFECTS OF HYDROXYUREA THERAPY IN SICKLE CELL PATIENTS Wouitchékpo V Tonassé Received Received
  1459-PS INFLUENCE OF BCL11A POLYMORPHYSMS ON FETAL HEMOGLOBIN LEVELS AND HAEMOLYSIS MARKERS IN SICKLE CELL ANEMIA PEDIATRIC PATIENTS NOT RECEIVING HYDROXYUREA Dalila Luciola Zanette Received Received
  1462-PS OUTCOME OF PHILADELPHIA CHROMOSOME-POSITIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS RECEIVING TYROSINE KINASE INHIBITOR MAINTENANCE THERAPY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Tuija Tapaninen Received Received
  1463-PS PD-1 OVEREXPRESSION ON BONE MARROW RESIDENT CD8+ MEMORY T-CELL SUBSETS COULD BE A PREDICTABLE MARKER FOR LEUKEMIA RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION. Mikhail Drokov Received Received
  1464-PS OUTCOME OF SECOND SOLID CANCER AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COHORT STUDY ON 4065 PATIENTS ON BEHALF OF THE COMPLICATIONS AND QUALITY OF LIFE WORKING PARTY OF THE EBMT Andre Tichelli Received Received
  1465-PS SIMILAR OUTCOMES OF REDUCED INTENSITY HAPLOIDENTICAL TRANSPLANTATION WHEN COMPARED TO MATCHED UNRELATED DONOR TRANSPLANT IN DIFFUSE LARGE B CELL LYMPHOMA. A JOINT ANALYSIS FROM CIBMTR-LC & EBMT-LWP. Katarina Gluic Received Received
  1466-PS TARGETING EXPANDED GUT HOMING EFFECTOR T CELL LINEAGES IN ACUTE INTESTINAL GRAFT VERSUS HOST DISEASE: IMPLICATIONS FOR VEDOLIZUMAB Polychronis Pavlidis Received Received
  1467-PS ELTROMBOPAG TO IMPROVE PLATELET RECOVERY IN HAPLOIDENTICAL STEM CELL TRANSPLANTS (HAPLO-SCT): RESULTS OF A PHASE II TRIALPLUS A COMPARISON TO CONTROL PATIENTS Uday Popat Received Received
  1468-PS ALLOGENEIC STEM CELL TRANSPLANTATION OVERCOMES THE NEGATIVE PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN TRANSPLANT ELIGIBLE PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA. Prateek Pophali Received Received
  1469-PS ASSOCIATION OF SOCIO-ECONOMIC FACTORS WITH SURVIVAL OF PATIENTS WHO EXPERIENCE SEVERE CLASSIC ACUTE GVHD AFTER ALLO-HSCT. A RETROSPECTIVE STUDY BY THE TRANSPLANT COMPLICATIONS WORKING PARTY, EBMT Andrzej Frankiewicz Received Received
  1470-PS COMPARISON OF REDUCED-INTENSITY CONDITIONING REGIMENS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA > 45 YEARS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION – A RETROSPECTIVE STUDY BY THE ALWP/EBMT Zinaida Peric Received Received
  1471-PS A PHASE I/II TRIAL OF INTRAVENOUS AZACITIDINE FOR ACUTE GVHD PROPHYLAXIS IN PATIENTS UNDERGOING MATCHED UNRELATED STEM CELL TRANSPLANTATION: INTERIM PHASE II RESULTS Mark Schroeder Received Received
  1474-PS PLASMA PRESEPSIN LEVEL IS A PREDICTIVE MARKER OF SEVERE ACUTE GVHD AFTER ALLO-HSCT: USEFULNESS AS A BIOMARKER OF ALLO-HSCT RELATED COMPLICATION Tatsuo Oyake Received Received
  1476-PS EFFECTS OF POST-AUTO-HSCT MRI BONE MARROW LESIONS ON PROGRESSION-FREE SURVIVAL IN PATIENTS WITH MM Maxim Solovev Received Received
  1477-PS COMBINED EVALUATION OF DISEASE RISK INDEX AND ABCG2 EXPRESSION IDENTIFY AML PATIENTS AT A VERY HIGH RISK OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Daniela Damiani Received Received
  1479-PS A NEW ULTRASONOGRAPHY-BASED SCORING SYSTEM IS EFFECTIVE DIAGNOSTIC TOOL FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION Mutsumi Nishida Received Received
  1481-PS CHANGES IN THE NUMBER OF BONE MARROW LESIONS AND TUMOUR MASS ON MRI IN PATIENTS WITH MM FOLLOWING AUTO-HSCT Maxim Solovev Received Received
  1483-PS ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION FOR NON-HODGKIN´S LYMPHOMA IN SWITZERLAND. 30 YEARS OF EXPERIENCE 1985-2017. Ekaterina Chigrinova Received Received
  1485-PS PROGNOSTICATION OF CHRONIC GRAFT VERSUS HOST DISEASE: THE IMPACT OF IMMUNE RECONSTITUTION. Fabio Serpenti Received Received
  1486-PS UTILIZATION AND OUTCOMES OF FERTILITY PRESERVATION TECHNIQUES IN WOMEN UNDERGOING ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT Alexandra Higgins Received Received
  1487-PS LOW INCIDENCE OF SYMPTOMATIC OSTEONECROSIS AFTER ALLOGENEIC HSCT IN CHILDREN WITH HIGH-RISK OR RELAPSED ALL – RESULTS OF THE ALL-SCT 2003 TRIAL Michaela Kuhlen Received Received
  1488-PS EARLY BLOOD STREAM INFECTION AFTER BMT IS ASSOCIATED WITH CYTOKINE DYSREGULATION AND POOR OVERALL SURVIVAL Kate Markey Received Received
  1489-PS REGRESSION TREE BASED MODEL FOR PREDICTING NON-RELAPSE MORTALITY IN AML PATIENTS ALLO-TRANSPLANTED IN FIRST COMPLETE REMISSION Anish Nair Received Received
  1492-PS SUBPOPULATIONS OF MONOCYTES AND B REGULATORY CELLS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE Antonija Babic Received Received
  1493-PS LIFESTYLE BEHAVIOR AMONG LYMPHOMA SURVIVORS AFTER HIGH DOSE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION Hanne Skjerven Bersvendsen Received Received
  1494-PS CTLA-4 GENE POLIMORPHISM INFLUENCE THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION Petra Kovy Received Received
  1497-PS INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF HEMORRHAGIC CYSTITIS ON HAPLOIDENTICAL TRANSPLANTATION María Perera Alvarez Received Received
  1500-PS CLOFARABINE- BASED CYTOREDUCTIVE TREATMENT FOLLOWED BY MYELOABLATIVE CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN WITH HIGH-RISK, RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES. Diego Medina Valencia Received Received
  1501-PS SELECTIVE INHIBITION OF OXIDATIVE PHOSPHORYLATION PREVENTS LETHAL GRAFT-VERSUS-HOST DISEASE WHILE MAINTAINING ANTITUMOR IMMUNITY Zachariah Mciver Received Received
  1502-PS AN UNBALANCED MONOCYTE MACROPHAGE POLARIZATION IN THE BONE MARROW MICROENVIRONMENT MAY CAUSE THE OCCURRENCE OF POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Hong-Yan Zhao Received Received
  1504-PS MURINE MODELS FOR ESTABLISHING STEROID REFRACTORY GVHD Tomomi Toubai Received Received
  1505-PS LOW-DOSE INTERLEUKIN-2 RESTORING HUMAN REGULATORY T CELL FUNCTION IN VITRO AS A POTENTIAL APPLICATION FOR GVHD THERAPY AFTER TRANSPLANTATION Tzeon-Jye Chiou Received Received
  1506-PS HYPOFRACTIONATED TOTAL LYMPHOID IRRADIATION BY HELICAL TOMOTHERAPY AND HIGH DOSE CHEMOTHERAPY AS CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA Fabio Guolo Received Received
  1509-PS HEMATOLOGICAL PHENOTYPES OF DIFFERENT ALPHA-THALASSAEMIA GENOTYPES CAUSING HYPOCHROMIC MICROCYTIC ANEMIA AT NEONATAL PERIOD Thidarat Suksangpleng Received Received
  1511-PS THE STRONG LINK BETWEEN PANCREAS AND HEART IN THALASSEMIA MAJOR. Antonella Meloni Received Received
  1513-PS PRE- AND POST-TRANSFUSION COMPLEMENT ACTIVATION IN TRANSFUSION-DEPENDENT ?-THALASSAEMIA Eleni Gavriilaki Received Received
  1514-PS ASSOCIATION OF CLINICAL PHENOTYPE OF THALASSEMIA WITH COMMON FETAL HEMOGLOBIN VARIANTS IN LEBANESE PATIENTS BEARING THE CODON 29 ?ETA GENE MUTATION Ali Taher Received Received
  1516-PS ASSOCIATION OF VITAMIN D AND RETINOID X RECEPTORS EXPRESSION AND VITAMIN D BINDING PROTEIN VARIANTS WITH BONE DENSITY IN THALASSEMIA CHILDREN Shaimaa Sahmoud Received Received
  1517-PS NEW OCCURRENCES OF MACROSCOPIC MYOCARDIAL FIBROSIS IN THALASSEMIA AT LONG TERM BY MULTIPLE FOLLOW-UP Antonella Meloni Received Received
  1518-PS COMMON LINK BETWEEN BONE AND HEART HEALTH IN THALASSEMIA MAJOR. Antonella Meloni Received Received
  1520-PS CEREBRAL IRON OVERLOAD IN BETA THALASSEMIA: DOES IT REALLY MATTER? Immacolata Tartaglione Received Received
  1521-PS LEPTIN IS ASSOCIATED WITH THE DEGREE OF ANEMIA AND THE ERYTHROPOIETIN LEVELS IN ? THALASSEMIA PATIENTS Osama Tanous Received Received
  1522-PS MUTATION SPECTRUM IN HBB, HBA1 AND HBA2 GENES IN PATIENTS FROM EUROPEAN PART OF RUSSIA Svetlana Mann Received Received
  1523-PS COMPREHENSIVE SCREENING FOR COEXISTING HETEROZYGOUS ?0-THALASSEMIA IN HEMOGLOBIN E TRAIT Piroonrut Wongprachar Received Received
  1524-PS INVOLVEMENT OF LEUCOCYTE DERIVED EXTRACELLULAR VESICLES IN THE PROCOAGULANT STATE FOUND IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA-RELATED CONDITION Adeline Wannez Received Received
  1525-PS ARE ALL DIRECT ORAL ANTICOAGULANTS EQUAL TO SAFETY AND EFFICACY? Begoña Navarro Almenzar Received Received
  1526-PS INCREASED PLATELET RESPONSE TO ENDOGENOUS AGONISTS, IN PRE-DIABETIC C57BL/6 MICE Zibusiso Mkandla Received Received
  1527-PS ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA AND ACUTE PANCREATITIS: VARIABLE AND RECIPROCAL PATHOPHYSIOLOGIC RELATIONSHIPS Qian Qin Received Received
  1528-PS EVALUATION OF LUPUS ANTICOAGULANT TESTING: A THREE YEAR EXPERIENCE Sergio Felipe Pinzon Received Received
  1530-PS APTT-BASED CLOT WAVEFORM ANALYSIS IN VARIOUS INFECTIONS Cheng Kiat Lawrence Ng Received Received
  1534-PS LABORATORY CRITERIA FOR THE DIAGNOSTIC RELIABILITY OF TESTS FOR DETECTION OF LUPUS ANTICOAGULANT IN PATIENTS WITH SUSPECTED ANTIPHOSPHOLIPID SYNDROME Valeriia Krasivska Received Received
  1535-PS THE COAGULATION SYSTEM FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS Elizaveta Efremova Received Received
  1536-PS PLATELET MAPPING BY THROMBOELASTOGRAPHY- ASSESSMENT OF PLATELET INHIBITION SECONDARY TO ANTIPLATELET THERAPY AFTER PCI Dibyendu De Received Received
  1537-PS IMMATURE PLATELET FRACTION: A USEFUL MARKER FOR IDENTIFYING THE CAUSE OF THROMBOCYTOPENIA AND PREDICTING PLATELET RECOVERY Eunyup Lee Received Received
  1538-PS PLATELETPHERESIS-ASSOCIATED LYMPHOPENIA IN FREQUENT PLATELET DONORS John Gansner Received Received
  1539-PS INTRACRANIAL HEMORRHAGE IN LEUKEMIA PATIENTS: PRELIMINARY RESULTS OF AN ONGOING NESTED CASE CONTROL STUDY LL Laura Cornelissen Received Received
  1540-PS QUALITY CONTROL IN CRYOPRESERVED POOLED PLATELETS: 9-YEAR EXPERIENCE IN A TRANSFUSION CENTRE. Pablo Romero Garcia Received Received
  1541-PS BACTERIAL CONTAMINANTS AND BIOFILMS EFFECT PLATELET ACTIVATION AND FUNCTION: IMPLICATIONS IN PLATELET TRANSFUSIONS Joels Wilson-Nieuwenhuis Received Received
  1543-PS MASSIVE TRANSFUSION PROTOCOLS - FRIEND OR FOE ? Moon Ley Tung Received Received
  1544-PS PLATELET-DERIVED MICROPARTICLES; THE EXPRESSION PROPERTIES AND POTENSIAL AS A SUBSTITUTE FOR PLATELETS Shima Azadpour Received Received
  1545--LB-P PSO EHA posters onsite Eva Hortas Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
20:42
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

23rd Congress of EHA

 

14-17 June 2018 Stockholm
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 14/06/2018 TO 14/06/2018
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.23EHA.2018 




PosterSessionOnline
Logo Draft
 
Logo Cert